Statement,Assertion,Summary (Tavily Answer),Relevant Docs,Final Verdict,Full Analysis,Citations
"Cancer classification represents one of the fundamental pillars of modern oncology, providing the essential framework for diagnosis, prognosis, treatment selection, and clinical communication.","Cancer classification provides essential framework for cancer diagnosis, prognosis, treatment selection, and clinical communication in modern oncology.","Cancer classification is crucial for diagnosis, prognosis, and treatment. The WHO International Classification of Diseases for Oncology (ICD-O) and Systematized Nomenclature of Medicine Clinical Terms (SNOMED-CT) are standard systems, but newer platforms like OncoTree aim to better meet modern genomic needs.","1. OncoTree: A Cancer Classification System for Precision Oncology - https://pmc.ncbi.nlm.nih.gov/articles/PMC8240791/
2. Global Consultation on Cancer Staging: promoting consistent ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/",Correct,"The TAVILY_SUMMARY explicitly states that 'Cancer classification is crucial for diagnosis, prognosis, and treatment,' directly supporting the assertion. The KNOWLEDGE_BASE_EXCERPTS also mention the 'International Classification of Diseases' in the context of nomenclature and coding for mortality data, which implies its foundational role.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8240791/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/']"
The systematic categorization of malignancies has evolved dramatically from purely morphological descriptions to sophisticated molecular characterizations that reflect our deeper understanding of cancer biology.,Systematic categorization of malignancies evolved from morphological descriptions to molecular characterizations due to deeper understanding of cancer biology.,Cancer classification now includes molecular characterizations alongside morphology. Targeted therapies based on molecular markers have transformed cancer management. This shift has improved patient outcomes and personalized treatment.,"1. Cancer: A pathologist's journey from morphology to molecular - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9287647/
2. Morphological diversity of cancer cells predicts prognosis across ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10995848/",Correct,"The TAVILY_SUMMARY confirms that 'Cancer classification now includes molecular characterizations alongside morphology' and that this shift is due to a deeper understanding of cancer biology, leading to 'targeted therapies based on molecular markers.' The RELEVANT_DOCS_LIST includes 'Cancer: A pathologist's journey from morphology to molecular,' further supporting this evolution.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9287647/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10686168/']"
"Histopathological classification represents the traditional cornerstone of cancer diagnosis, based on the microscopic examination of tissue samples to determine cellular morphology, tissue architecture, and differentiation patterns.","Histopathological classification for cancer diagnosis is based on microscopic examination of tissue samples for cellular morphology, tissue architecture, and differentiation patterns.",Histopathological classification is key for cancer diagnosis via tissue sample examination. It identifies cellular morphology and tissue architecture. AI enhances precision and efficiency in this analysis.,"1. AI in Histopathology Explorer for comprehensive analysis of the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11904230/
2. Detection and Classification of Cancer from Microscopic Biopsy ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4782618/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Histopathological classification is key for cancer diagnosis via tissue sample examination. It identifies cellular morphology and tissue architecture.' The RELEVANT_DOCS_LIST also refers to 'AI in Histopathology Explorer' and 'Detection and Classification of Cancer from Microscopic Biopsy,' reinforcing the microscopic examination aspect.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11904230/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4782618/']"
Cancer grading describes the microscopic appearance of the tumor's cells and tissue.,Cancer grading describes the microscopic appearance of tumor cells and tissue.,"Cancer grading evaluates how abnormal tumor cells appear under a microscope. Higher grades indicate more abnormal cells, suggesting faster growth and worse prognosis. Lower grades mean cells look more like normal cells.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. In brief: Cancer: What do the codes in the doctor's letter mean? - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK279426/",Correct,"The TAVILY_SUMMARY explicitly states that 'Cancer grading evaluates how abnormal tumor cells appear under a microscope,' which directly confirms the assertion that cancer grading describes the microscopic appearance of tumor cells and tissue.","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://www.ncbi.nlm.nih.gov/books/NBK279426/']"
Low-grade tumors have relatively normal-appearing cells and tissue structures.,Low-grade tumors exhibit relatively normal-appearing cells and tissue structures microscopically.,Low-grade tumors have normal-looking cells and structures. They are well-differentiated and usually less aggressive. Higher-grade tumors have more abnormal cells and are often more dangerous.,"1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Low-Grade Gliomas - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK560668/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Low-grade tumors have normal-looking cells and structures' and are 'well-differentiated and usually less aggressive.'","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://www.ncbi.nlm.nih.gov/books/NBK560668/']"
These tumors are considered well-differentiated.,Low-grade tumors are classified as well-differentiated.,Well-differentiated tumors often have a better prognosis and are typically managed with somatostatin analogs. High-grade well-differentiated tumors may require PRRT and everolimus. Treatment outcomes depend on tumor grade and individual patient characteristics.,"1. Advances in the Diagnosis and Management of Well-Differentiated ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7080342/
2. Treatment Outcomes of Well-Differentiated High-Grade ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/33496040/",Correct,"The TAVILY_SUMMARY states that 'Well-differentiated tumors often have a better prognosis' and the summary for Item 5 explicitly linked 'Low-grade tumors' to being 'well-differentiated,' confirming the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7080342/', 'https://pubmed.ncbi.nlm.nih.gov/33496040/']"
Higher-grade tumors have more abnormal-appearing cells and tissue that is structured abnormally.,Higher-grade tumors exhibit more abnormal-appearing cells and abnormally structured tissue microscopically.,Higher-grade tumors have more abnormal cells and disorganized tissue. They are typically more aggressive and have a worse prognosis. Higher-grade tumors are poorly differentiated.,"1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. The Molecular Basis of Cancer-Cell Behavior - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK26902/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Higher-grade tumors have more abnormal cells and disorganized tissue' and are 'typically more aggressive and have a worse prognosis.'","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://www.ncbi.nlm.nih.gov/books/NBK26902/']"
"The main histopathological features that classify brain tumors include atypia, anaplasia, microscopic proliferation, and necrosis.","Histopathological features classifying brain tumors include atypia, anaplasia, microscopic proliferation, and necrosis.","The main histopathological features classifying brain tumors are atypia, anaplasia, microscopic proliferation, and necrosis. High-grade gliomas exhibit all these features, while low-grade gliomas show only atypia. Necrosis is a key feature of high-grade tumors.","1. Low-Grade Gliomas - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK560668/
2. Histologic and Molecular Features of Diffuse Gliomas - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7133074/",Correct,"The TAVILY_SUMMARY explicitly confirms the assertion: 'The main histopathological features classifying brain tumors are atypia, anaplasia, microscopic proliferation, and necrosis.' The RELEVANT_DOCS_LIST also includes documents on 'Low-Grade Gliomas' and 'Histologic and Molecular Features of Diffuse Gliomas,' which are consistent with this classification context.","['https://www.ncbi.nlm.nih.gov/books/NBK560668/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7133074/']"
These characteristics form the basis for grading systems across different cancer types.,"Atypia, anaplasia, microscopic proliferation, and necrosis form the basis for cancer grading systems.","Cancer grading assesses tumor cell differentiation and structure; low-grade tumors are well-differentiated, while high-grade tumors are poorly differentiated and more aggressive. The WHO system grades tumors from 1 to 3 based on these features.","1. Cancer Classification at the Crossroads - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC7226085/
2. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/",Correct,"The TAVILY_SUMMARY states that 'Cancer grading assesses tumor cell differentiation and structure' and that 'The WHO system grades tumors from 1 to 3 based on these features,' implying that features like atypia, anaplasia, proliferation, and necrosis (which describe differentiation and structure, as established in previous items) form the basis for grading systems.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7226085/', 'https://www.ncbi.nlm.nih.gov/books/NBK553187/']"
Higher-grade tumors are typically more aggressive and have a worse prognosis.,Higher-grade tumors are typically more aggressive and associated with a worse prognosis.,Higher-grade tumors are typically more aggressive. They often have a worse prognosis. Tumor grade is a key indicator of tumor behavior.,"1. Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8064390/
2. Cancer cell differentiation heterogeneity and aggressive behavior in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3339553/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Higher-grade tumors are typically more aggressive. They often have a worse prognosis. Tumor grade is a key indicator of tumor behavior.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8064390/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3339553/']"
They are described as poorly differentiated.,Higher-grade tumors are described as poorly differentiated.,"Poorly differentiated neoplasms often include non-Hodgkin lymphoma and poorly differentiated neuroendocrine carcinoma. These tumors can be treated effectively, and molecular studies help identify specific diagnoses. Extragonadal germ cell tumors respond well to chemotherapy.","1. Poorly Differentiated Neoplasms - Holland-Frei Cancer Medicine - https://www.ncbi.nlm.nih.gov/books/NBK13301/
2. Poorly Differentiated Carcinoma of Unknown Primary Site - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK13171/",Flagged for Review,Failed to parse JSON batch response.,
The highest-grade tumors are termed undifferentiated.,Highest-grade tumors are termed undifferentiated.,The highest-grade tumors are termed undifferentiated. They are poorly differentiated and typically more aggressive. Undifferentiated tumors have a worse prognosis.,"1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Treatment and outcomes in undifferentiated and dedifferentiated ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9024191/",Flagged for Review,Failed to parse JSON batch response.,
The World Health Organization has classified CNS tumors into seven categories in its most recent revision of its classification system.,World Health Organization (WHO) classified CNS tumors into seven categories in its most recent classification revision.,"The WHO classifies CNS tumors into seven categories in its latest revision, emphasizing molecular diagnostics and introducing new entities and grading systems.","1. The 2021 WHO Classification of Tumors of the Central Nervous ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/
2. 2021 World Health Organization Classification of Brain Tumors - https://pubmed.ncbi.nlm.nih.gov/38085892/",Flagged for Review,Failed to parse JSON batch response.,
**Grade IV**: Highly malignant tumors with rapid progression and poor prognosis,"WHO Grade IV CNS tumors are highly malignant, with rapid progression and poor prognosis.",Grade IV tumors are highly malignant with rapid progression and poor prognosis. Glioblastoma is a common Grade IV tumor with a median survival of 14 months. Treatment options are limited and often involve radiotherapy.,"1. Recurrent Glioblastoma: A Review of the Treatment Options - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10487236/
2. Treatment Patterns and Outcomes of Patients with Grade 4 Glioma ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10046893/",Correct,"The TAVILY_SUMMARY explicitly states that Grade IV tumors are highly malignant with rapid progression and poor prognosis, which directly matches the assertion. The relevant documents also discuss Grade 4 gliomas, confirming the context of CNS tumors.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10487236/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10046893/']"
"The histologic classification of epithelial tumors of the uterine cervix by the World Health Organization (WHO) separates them into three main groups: squamous cell carcinomas, adenocarcinomas, and other epithelial tumors.","WHO histologic classification of uterine cervix epithelial tumors separates them into squamous cell carcinomas, adenocarcinomas, and other epithelial tumors.","The WHO classifies uterine cervical epithelial tumors into three main groups: squamous cell carcinomas, adenocarcinomas, and other epithelial tumors. Adenosquamous carcinomas, which combine both squamous and glandular cells, are also recognized. Non-small-cell neuroendocrine carcinomas exist but are not listed in the current WHO classification.","1. Histologic classification of epithelial tumors - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12450/
2. 2020 WHO Classification of Female Genital Tumors - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8494521/",Correct,"The TAVILY_SUMMARY explicitly confirms that the WHO classifies uterine cervical epithelial tumors into squamous cell carcinomas, adenocarcinomas, and other epithelial tumors.","['https://www.ncbi.nlm.nih.gov/books/NBK12450/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8494521/']"
The majority of cervical carcinomas are squamous cell carcinomas that are classified as either large cell nonkeratinizing or large cell keratinizing.,"The majority of cervical carcinomas are squamous cell carcinomas, classified as large cell nonkeratinizing or large cell keratinizing.","The majority of cervical carcinomas are squamous cell carcinomas, classified as either large cell nonkeratinizing or large cell keratinizing. Adenosquamous carcinomas account for 5% to 25% of cervical carcinomas. Adenosquamous carcinomas are mixed tumors with both squamous and glandular cells.","1. Histologic classification of epithelial tumors - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12450/
2. Cervical Squamous Cell Carcinoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK559075/",Correct,"The TAVILY_SUMMARY explicitly states that the majority of cervical carcinomas are squamous cell carcinomas, classified as large cell nonkeratinizing or large cell keratinizing.","['https://www.ncbi.nlm.nih.gov/books/NBK12450/', 'https://www.ncbi.nlm.nih.gov/books/NBK559075/']"
The Gleason score is the primary initial histologic assessment tool used to grade prostate malignancies and has proven to have significant prognostic value.,The Gleason score is the primary initial histologic assessment tool for grading prostate malignancies and has significant prognostic value.,"The Gleason score is a key tool for grading prostate cancer, indicating prognosis, and is based on glandular pattern. It ranges from 1 to 5, with lower scores indicating more normal gland patterns and higher scores indicating more abnormal cancer cells. It helps determine the aggressiveness and treatment of prostate cancer.","1. Gleason Score - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553178/
2. Prostate Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470550/",Correct,"The TAVILY_SUMMARY confirms that the Gleason score is a key tool for grading prostate cancer and indicates prognosis, supporting its role as a primary assessment tool with significant prognostic value.","['https://www.ncbi.nlm.nih.gov/books/NBK553178/', 'https://www.ncbi.nlm.nih.gov/books/NBK470550/']"
The Gleason grade is primarily based on the architecture or arrangement of the malignant cells within the tumor as well as other factors such as the degree of differentiation.,"Gleason grade is primarily based on the architecture or arrangement of malignant cells within the tumor, and degree of differentiation.","The Gleason grade assesses prostate cancer based on cell arrangement and differentiation, ranging from 1 (normal) to 5 (abnormal). It helps predict cancer behavior and prognosis. The score combines two patterns, with higher scores indicating worse outcomes.","1. Gleason Score - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553178/
2. Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3? - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2717753/",Correct,The TAVILY_SUMMARY explicitly states that the Gleason grade assesses prostate cancer based on cell arrangement and differentiation.,"['https://www.ncbi.nlm.nih.gov/books/NBK553178/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2717753/']"
"Since the prostate is a gland, the less glandular the microscopic appearance, the higher the Gleason grade, ranging from 1 to a maximum of 5.","In prostate cancer, less glandular microscopic appearance correlates with a higher Gleason grade, ranging from 1 to 5.","The Gleason grade ranges from 1 to 5, with less glandular appearance indicating a higher grade. The Gleason score sums primary and secondary patterns, ranging from 2 to 10. Higher Gleason scores indicate more aggressive prostate cancer.","1. Gleason Score - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553178/
2. Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3? - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2717753/",Correct,"The TAVILY_SUMMARY explicitly states that the Gleason grade ranges from 1 to 5, and a less glandular appearance indicates a higher grade.","['https://www.ncbi.nlm.nih.gov/books/NBK553178/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2717753/']"
Differentiation refers to how closely cancer cells resemble normal cells of the same tissue type.,Cancer cell differentiation refers to how closely cancer cells resemble normal cells of the same tissue type.,"Differentiation refers to how closely cancer cells resemble normal cells. Cancer cells often fail to differentiate normally, resulting in abnormal proliferation. This defective differentiation is a key characteristic of cancer cells.","1. Cell Proliferation and Differentiation - Holland-Frei Cancer Medicine - https://www.ncbi.nlm.nih.gov/books/NBK13866/
2. The Development and Causes of Cancer - The Cell - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK9963/",Correct,The TAVILY_SUMMARY explicitly defines differentiation as how closely cancer cells resemble normal cells.,"['https://www.ncbi.nlm.nih.gov/books/NBK13866/', 'https://www.ncbi.nlm.nih.gov/books/NBK9963/']"
"Well-differentiated tumors closely resemble normal tissue architecture and cellular morphology, while poorly differentiated tumors show significant deviation from normal patterns.",Well-differentiated tumors resemble normal tissue architecture and cellular morphology; poorly differentiated tumors deviate significantly from normal patterns.,"Well-differentiated tumors closely resemble normal tissue, while poorly differentiated tumors show significant deviation. Poor differentiation often correlates with worse prognosis and higher risk of recurrence and metastasis. Tumor differentiation is a key factor in determining treatment outcomes.","1. TUMOR CELL MORPHOLOGY - Comparative Oncology - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK9553/
2. Well-Differentiated Squamous Cell Carcinoma: Is Histological ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8060007/",Correct,"The TAVILY_SUMMARY explicitly states that well-differentiated tumors closely resemble normal tissue, while poorly differentiated tumors show significant deviation.","['https://www.ncbi.nlm.nih.gov/books/NBK9553/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8060007/']"
"Cancer cells are usually less developed (differentiated) than healthy cells, and not specialized for a specific task.",Cancer cells are typically less differentiated and less specialized than healthy cells.,"Cancer cells are usually less differentiated than healthy cells, often lacking specialization. They proliferate uncontrollably and show reduced adhesion. Their abnormal elasticity distinguishes them from normal cells.","1. The Development and Causes of Cancer - The Cell - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK9963/
2. Comparison of Cancer Cell Elasticity by Cell Type - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7391204/",Correct,The TAVILY_SUMMARY explicitly states that cancer cells are usually less differentiated and often lack specialization compared to healthy cells.,"['https://www.ncbi.nlm.nih.gov/books/NBK9963/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7391204/']"
Grading is done to assess how much the tumor cells differ from healthy cells.,Tumor grading assesses the degree of difference between tumor cells and healthy cells.,Grading assesses how much tumor cells differ from healthy cells. Tumors are graded based on their appearance under a microscope. Higher grades indicate more aggressive tumors.,"1. In brief: Cancer: What do the codes in the doctor's letter mean? - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK279426/
2. TUMOR CELL MORPHOLOGY - Comparative Oncology - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK9553/",Correct,The TAVILY_SUMMARY explicitly states that grading assesses how much tumor cells differ from healthy cells.,"['https://www.ncbi.nlm.nih.gov/books/NBK279426/', 'https://www.ncbi.nlm.nih.gov/books/NBK9553/']"
This proliferation marker has become increasingly important across multiple cancer types for determining growth potential and prognosis.,Ki-67 proliferation marker is increasingly important across multiple cancer types for determining growth potential and prognosis.,Ki-67 is a key proliferation marker used to assess growth potential and prognosis in various cancers. It is present during all active cell cycle phases except G0. High Ki-67 levels indicate aggressive tumor behavior.,"1. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8430879/
2. The Prognostic Relevance of the Proliferation Markers Ki-67 and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7577119/",Flagged for Review,"Error occurred during batch fact checking: Invalid operation: The `response.text` quick accessor requires the response to contain a valid `Part`, but none were returned. The candidate's [finish_reason](https://ai.google.dev/api/generate-content#finishreason) is 2.",
"In adenocarcinomas, the degree of glandular formation is a key grading criterion.","In adenocarcinomas, the degree of glandular formation is a key grading criterion.","In adenocarcinomas, glandular formation is key for grading; grade 1 has mostly glands, grade 2 has more solid areas, and grade 3 has mostly solid growth. Higher solid growth correlates with worse prognosis.","1. Grading of Endocervical Adenocarcinomas: Review of the Literature ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7969159/
2. Atypical Glandular Cells (AGS) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK564318/",Correct,"The TAVILY_SUMMARY explicitly states that glandular formation is a key criterion for grading adenocarcinomas, with different grades correlating to the proportion of glandular versus solid growth.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC7969159/']
"Well-differentiated adenocarcinomas maintain recognizable glandular patterns, while poorly differentiated tumors lose this architecture and may appear as solid sheets of cells.","Well-differentiated adenocarcinomas maintain glandular patterns; poorly differentiated tumors lose this architecture, appearing as solid sheets of cells.","Well-differentiated adenocarcinomas have clear glandular structures, while poorly differentiated tumors lack this organization and appear as dense cell masses. This distinction is crucial for cancer diagnosis.","1. Extremely well-differentiated adenocarcinoma of the stomach - https://pmc.ncbi.nlm.nih.gov/articles/PMC8935003/
2. CANCER DIAGNOSIS - Comparative Oncology - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK9550/",Correct,"The TAVILY_SUMMARY confirms that well-differentiated adenocarcinomas retain clear glandular structures, whereas poorly differentiated ones lose this organization and appear as dense cell masses.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC8935003/']
"For squamous cell carcinomas, keratinization and the presence of intercellular bridges are important differentiation markers.",Keratinization and intercellular bridges are important differentiation markers for squamous cell carcinomas.,Squamous cell carcinomas are characterized by keratinization and intercellular bridges. These features are key for diagnosis. Histological examination confirms the presence of these markers.,"1. Squamous Cell Lung Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK564510/
2. Deciphering the cells of origin of squamous cell carcinomas - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7170720/",Correct,The TAVILY_SUMMARY explicitly states that keratinization and intercellular bridges are characteristic and key diagnostic features for squamous cell carcinomas.,['https://www.ncbi.nlm.nih.gov/books/NBK564510/']
Keratinizing carcinoma is characterized by cells with very hyperchromatic nuclei and densely eosinophilic cytoplasm growing in irregular invasive nests.,Keratinizing carcinoma is characterized by cells with hyperchromatic nuclei and densely eosinophilic cytoplasm growing in irregular invasive nests.,Keratinizing carcinoma features hyperchromatic nuclei and eosinophilic cytoplasm in invasive nests. It is a type of squamous cell carcinoma. This type is characterized by well-formed keratin pearls.,"1. Histologic classification of epithelial tumors - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12450/
2. TUMORS OF THE ALIMENTARY SYSTEM - Comparative Oncology - https://www.ncbi.nlm.nih.gov/books/NBK9565/",Correct,"The TAVILY_SUMMARY confirms that keratinizing carcinoma is characterized by cells with hyperchromatic nuclei and eosinophilic cytoplasm, arranged in invasive nests.",['https://www.ncbi.nlm.nih.gov/books/NBK12450/']
"Many of these nests have central \""pearls\"" that contain abundant keratin.","Many nests of keratinizing carcinoma have central \""pearls\"" containing abundant keratin.","Keratin-filled central ""pearls"" are common in squamous cell carcinomas. These ""pearls"" are dense aggregates of keratinocytes. Keratin-filled nests are also seen in keratoacanthomas.","1. Skin adnexal neoplasms—part 1: An approach to tumours of the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC1860623/
2. Keratoacanthoma versus Squamous-Cell Carcinoma - https://pmc.ncbi.nlm.nih.gov/articles/PMC11503433/",Correct,"The TAVILY_SUMMARY confirms that keratin-filled central ""pearls"" are common in squamous cell carcinomas, which includes keratinizing carcinoma.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC1860623/']
"Despite these advances and guidelines, there remains a considerable difference in Gleason grading, even between experienced pathologists.","Considerable inter-observer variability exists in Gleason grading, even among experienced pathologists.","Despite advances, Gleason grading shows significant variability even among experienced pathologists. Studies show moderate to substantial agreement among experts but lower among general pathologists. AI systems show mixed results in improving grading consistency.","1. Gleason Score - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553178/
2. Identification of areas of grading difficulties in prostate cancer and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7683442/",Correct,"The TAVILY_SUMMARY explicitly states that significant inter-observer variability exists in Gleason grading, even among experienced pathologists.",['https://www.ncbi.nlm.nih.gov/books/NBK553178/']
"Studies have further demonstrated considerable variation between pathologists in colorectal cancer grading, suggesting the importance of tumor staging for prognosis.","Studies demonstrate considerable inter-pathologist variation in colorectal cancer grading, suggesting importance of tumor staging for prognosis.","Pathologists show significant variation in grading colorectal cancer, impacting prognosis. Tumor staging is crucial for prognosis, but grading differences affect outcomes. Consistent staging systems are needed.","1. Pathological Features and Prognostication in Colorectal Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8700531/
2. Variation in Pathologist Classification of Colorectal Adenomas and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6049074/",Correct,The TAVILY_SUMMARY confirms significant inter-pathologist variation in grading colorectal cancer and highlights the crucial role of tumor staging for prognosis. The knowledge base also supports the importance of staging for survival.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC8700531/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6049074/']"
"It is becoming evident that histopathologic diagnosis is insufficient to accurately predict tumor behavior and prognosis, particularly with the problem of interobserver variability with respect to histopathologic grade.","Histopathologic diagnosis is insufficient to accurately predict tumor behavior and prognosis, particularly due to interobserver variability in histopathologic grade.",Histopathologic diagnosis alone is often insufficient for predicting tumor behavior due to interobserver variability. Deep learning models can quantify tumor microenvironments to improve prognostic prediction. Advanced techniques beyond traditional histopathology are needed for better accuracy.,"1. Prognostic prediction based on histopathologic features of tumor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10117979/
2. Histopathology of Neuro-epithelial Central Nervous system Tumors - https://www.ncbi.nlm.nih.gov/books/NBK13150/",Correct,"The TAVILY_SUMMARY explicitly states that histopathologic diagnosis alone is often insufficient for predicting tumor behavior and prognosis, citing interobserver variability as a key reason.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC10117979/']
This recognition has driven the integration of molecular features into modern classification systems.,Recognition of histopathologic diagnosis limitations has driven the integration of molecular features into modern cancer classification systems.,"Modern classification systems now integrate molecular features, enhancing cancer diagnosis and prognosis. The 2023 FIGO staging system includes molecular classifications. Clinical sequencing and molecular markers improve cancer management.","1. Moving into the Modern Era of Molecular Classification for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10976916/
2. Molecular Classification of Endometrial Cancer and the 2023 FIGO ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10452831/",Correct,"The TAVILY_SUMMARY confirms that modern cancer classification systems now integrate molecular features to enhance diagnosis and prognosis, which is a direct response to the limitations of traditional histopathologic methods.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10976916/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10452831/']"
It is primarily used in solid tumors and can assist in prognostic cancer staging.,TNM classification is primarily used in solid tumors and assists in prognostic cancer staging.,"The TNM Classification is used for staging solid tumors and helps in cancer prognosis. It assesses tumor size, lymph node involvement, and metastasis. This system aids in determining the stage and severity of cancer.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Cancer Biomarkers - Emerging Trends and Clinical Implications for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7616034/",Correct,The TAVILY_SUMMARY explicitly states that the TNM classification is used for staging solid tumors and assists in cancer prognosis.,['https://www.ncbi.nlm.nih.gov/books/NBK553187/']
A standard classification system improves provider communication and facilitates information sharing and research across populations.,"A standard classification system improves provider communication, facilitates information sharing, and research across populations.","A standard classification system enhances provider communication, aids information sharing, and supports research across populations. The TNM Classification is one such system used for cancer staging. Further research is needed to apply these systems broadly.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. A systematic review of classifications systems to determine ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8022082/",Correct,"The TAVILY_SUMMARY explicitly states that a standard classification system enhances provider communication, aids information sharing, and supports research across populations, directly confirming the assertion.","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'A systematic review of classifications systems to determine ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8022082/']"
"The system is based on assessing the tumor, regional lymph nodes, and distant metastasis.","The TNM system is based on assessing the tumor (T), regional lymph nodes (N), and distant metastasis (M).","The TNM system assesses tumors, regional lymph nodes, and distant metastasis to determine cancer stage. The eighth edition of TNM staging for lung cancer includes updated definitions for T, N, and M categories. This system is widely used for cancer prognosis and treatment planning.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6058324/",Correct,"The TAVILY_SUMMARY confirms that the TNM system assesses tumors, regional lymph nodes, and distant metastasis to determine cancer stage, which aligns with the assertion.","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6058324/']"
**T (Tumor)**: Used to describe the size of the primary tumor and its invasion into adjacent tissues.,T (Tumor) in TNM describes the size of the primary tumor and its invasion into adjacent tissues.,"""T"" in TNM classification describes the size and extent of the primary tumor, with T1 to T4 indicating increasing size and invasion, and T0 indicating no tumor present. T-values vary based on tumor type and location.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Cancer Classification at the Crossroads - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC7226085/",Correct,"The TAVILY_SUMMARY states that 'T' in TNM classification describes the size and extent of the primary tumor, indicating increasing size and invasion, which directly supports the assertion.","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'Cancer Classification at the Crossroads - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC7226085/']"
"T0 indicates no evidence of tumor is present, while T1-T4 is used to identify the size and extension of the tumor, with progressive enlargement and invasiveness from T1 to T4.","T0 in TNM indicates no tumor; T1-T4 identify increasing tumor size, extension, enlargement, and invasiveness.","T0 means no tumor is present, while T1 to T4 indicate increasing tumor size and invasiveness, with T4 being the most advanced.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. In brief: Cancer: What do the codes in the doctor's letter mean? - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK279426/",Correct,"The TAVILY_SUMMARY explicitly states that 'T0 means no tumor is present, while T1 to T4 indicate increasing tumor size and invasiveness, with T4 being the most advanced,' which fully supports the assertion.","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', ""In brief: Cancer: What do the codes in the doctor's letter mean? - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK279426/""]"
**N (Nodes)**: Describes whether or not regional lymph nodes are affected.,N (Nodes) in TNM describes regional lymph node involvement.,"N describes regional lymph node involvement in cancer staging: N0 indicates no spread, N1 to N3 indicate increasing spread to regional nodes. Nx means nodes cannot be assessed.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/",Correct,"The TAVILY_SUMMARY clearly states that 'N describes regional lymph node involvement in cancer staging,' directly confirming the assertion.","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/']"
These are lymph nodes that are located in the drainage area of the affected organ.,Regional lymph nodes are located in the drainage area of the affected organ.,Lymph nodes located in the drainage area of the affected organ are called regional lymph nodes. They filter lymphatic fluid and can indicate disease spread. Examples include celiac nodes for the stomach and axillary nodes for the breast.,"1. Nomenclature and Lymphatic Drainage Patterns of Abdominal ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9748447/
2. Lymphadenopathy - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK513250/",Correct,"The TAVILY_SUMMARY explicitly defines regional lymph nodes as 'lymph nodes located in the drainage area of the affected organ,' which directly supports the assertion.","['Nomenclature and Lymphatic Drainage Patterns of Abdominal ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9748447/', 'Lymphadenopathy - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK513250/']"
"**M (Metastases)**: Tells us whether or not the tumor has spread to other parts of the body, forming distant metastases.","M (Metastases) in TNM indicates tumor spread to other body parts, forming distant metastases.","M indicates whether the tumor has spread to other parts of the body. M0 means no distant metastasis, while M1 indicates the presence of distant metastasis. This classification is part of the TNM staging system.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Clinical Relevance of Targeting Cancer Metastases - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK154382/",Correct,"The TAVILY_SUMMARY states that 'M indicates whether the tumor has spread to other parts of the body. M0 means no distant metastasis, while M1 indicates the presence of distant metastasis,' which directly confirms the assertion.","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'Clinical Relevance of Targeting Cancer Metastases - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK154382/']"
The TNM classification devised by the International Union Against Cancer (UICC) and accepted by the American Joint Commission on Cancer Staging is a world standard.,The TNM classification by UICC and AJCC is an international standard for cancer staging.,"The TNM classification, created by the UICC and adopted by the AJCC, is the worldwide standard for cancer staging. It assesses tumor size (T), regional lymph node involvement (N), and the presence of distant metastasis (M). This system helps doctors determine cancer stage and treatment.","1. Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/
2. The TNM classification of lung cancer—a historic perspective - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11635265/",Correct,"The TAVILY_SUMMARY explicitly states that 'The TNM classification, created by the UICC and adopted by the AJCC, is the worldwide standard for cancer staging,' directly supporting the assertion.","['Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/', 'The TNM classification of lung cancer—a historic perspective - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11635265/']"
"The TNM is based on the clinical features of tumor (T), the regional lymph nodes (N), and the presence or absence of distant metastases (M).","TNM classification is based on clinical features of tumor (T), regional lymph nodes (N), and distant metastases (M).","The TNM classification assesses cancer based on tumor size (T), regional lymph node involvement (N), and distant metastasis (M). It is a standard used worldwide for cancer staging. The TNM is crucial for determining treatment and prognosis.","1. Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/
2. Implementation of the 9th TNM for lung cancer: practical insights for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12165876/",Correct,"The TAVILY_SUMMARY confirms that 'The TNM classification assesses cancer based on tumor size (T), regional lymph node involvement (N), and distant metastasis (M),' which aligns with the assertion.","['Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/', 'Implementation of the 9th TNM for lung cancer: practical insights for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12165876/']"
The Union for International Cancer Control (UICC) TNM classification of malignant tumours is a system based on description of the spread and size of the cancer.,UICC TNM classification of malignant tumors is based on describing cancer spread and size.,"The TNM classification system assesses the size of the tumor, involvement of regional lymph nodes, and presence of distant metastasis to classify and stage cancer. It is used globally for cancer prognosis and treatment planning. The latest edition is the eighth from the UICC.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Eighth Edition of the UICC Classification of Malignant Tumours - https://pubmed.ncbi.nlm.nih.gov/29209757/",Correct,"The TAVILY_SUMMARY states that 'The TNM classification system assesses the size of the tumor, involvement of regional lymph nodes, and presence of distant metastasis to classify and stage cancer,' which directly supports the assertion that it is based on describing cancer spread (nodes, metastasis) and size (tumor).","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'Eighth Edition of the UICC Classification of Malignant Tumours - https://pubmed.ncbi.nlm.nih.gov/29209757/']"
"It documents the size of the tumour (T), affected lymph nodes (N) and distant metastases (M).","UICC TNM classification documents tumor size (T), affected lymph nodes (N), and distant metastases (M).","The TNM classification documents tumor size (T), affected lymph nodes (N), and distant metastases (M). The latest edition includes updated definitions and staging for lung cancer. The tumor size is based on the greatest dimension of the lesion.","1. Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/
2. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6058324/",Correct,"The TAVILY_SUMMARY explicitly states that the TNM classification documents tumor size (T), affected lymph nodes (N), and distant metastases (M).","['Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/', 'The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6058324/']"
The TNM stages are based either on clinical description or on pathological classification (pTNM).,TNM stages are based on clinical description or pathological classification (pTNM).,"TNM stages classify cancer based on tumor size, lymph node involvement, and metastasis. The pTNM stage uses pathological data. The TNM system is widely used for cancer prognosis.","1. Table 2. Definitions of pTNM Stages 1A and IB a - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65766.6/table/CDR0000062911__374/?report=objectonly
2. Pathological tumor-node-metastasis (pTNM) staging for papillary ... - https://pubmed.ncbi.nlm.nih.gov/9360506/",Correct,"The TAVILY_SUMMARY confirms that 'The pTNM stage uses pathological data,' indicating that TNM stages can be based on pathological classification. Clinical description is the other primary method for TNM staging.","['Table 2. Definitions of pTNM Stages 1A and IB a - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65766.6/table/CDR0000062911__374/?report=objectonly', 'Pathological tumor-node-metastasis (pTNM) staging for papillary ... - https://pubmed.ncbi.nlm.nih.gov/9360506/']"
"The TNM system helps to establish the anatomic extent of the disease, and the combination of the 3 factors can define the overall tumor stage.","The TNM system establishes the anatomic extent of disease, with combined factors defining the overall tumor stage.","The TNM system stages cancer by assessing tumor size (T), lymph node involvement (N), and metastasis (M). Combined, these factors define the overall tumor stage from I to IV, with IV being the most severe. Stage 0 indicates carcinoma in situ.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. A systematic selection method for the development of cancer staging ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4250448/",Correct,"The TAVILY_SUMMARY states that 'The TNM system stages cancer by assessing tumor size (T), lymph node involvement (N), and metastasis (M). Combined, these factors define the overall tumor stage from I to IV,' directly supporting the assertion.","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'A systematic selection method for the development of cancer staging ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4250448/']"
"This method allows for simplification, with cancers staged from I-IV, with stage IV being the most severe stage:","Cancers are staged I-IV using TNM, with Stage IV representing the most severe stage.","Cancers are staged using the TNM system, ranging from I to IV, with IV being the most severe stage indicating metastatic cancer. Stage 0 is carcinoma in situ. The TNM system simplifies cancer staging.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. A systematic selection method for the development of cancer staging ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4250448/",Correct,"The TAVILY_SUMMARY explicitly states, 'Cancers are staged using the TNM system, ranging from I to IV, with IV being the most severe stage indicating metastatic cancer.'","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'A systematic selection method for the development of cancer staging ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4250448/']"
"**Stage 0**: Indicates carcinoma in situ, which is not considered cancerous but may become cancer","Stage 0 in cancer staging indicates carcinoma in situ, not considered cancerous but may become cancer.","Stage 0 cancer indicates carcinoma in situ, which is not cancerous but has potential to become cancer. It is the earliest stage of cancer. Stage 0 is often treated to prevent progression.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Ductal Carcinoma In Situ: Terminology, Classification, and Natural ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5161057/",Correct,"The TAVILY_SUMMARY confirms that 'Stage 0 cancer indicates carcinoma in situ, which is not cancerous but has potential to become cancer.'","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'Ductal Carcinoma In Situ: Terminology, Classification, and Natural ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5161057/']"
**Stage I**: Early-stage cancer confined to the organ of origin,"Stage I cancer is early-stage, confined to the organ of origin.","Stage I cancer is localized, confined to the organ, with no spread to lymph nodes or distant sites. It includes T1-T2 tumors, N0, M0. This early stage indicates minimal invasion.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Table 3. Definitions of TNM Stages IA1, IA2, IA3, and IB a - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65865.23/table/CDR0000062932__485404/?report=objectonly",Correct,"The TAVILY_SUMMARY states, 'Stage I cancer is localized, confined to the organ, with no spread to lymph nodes or distant sites,' which aligns with the assertion.","['TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'Table 3. Definitions of TNM Stages IA1, IA2, IA3, and IB a - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65865.23/table/CDR0000062932__485404/?report=objectonly']"
**Stage II**: Cancer with local extension or minimal nodal involvement,Stage II cancer involves local extension or minimal nodal involvement.,"Stage II cancer involves local tumor growth without distant metastasis but with minimal nodal involvement. Stage II colon cancer includes stages IIA, IIB, and IIC, with varying recurrence risks. Adjuvant chemotherapy may benefit some patients but not all.","1. Chemotherapy for Stage II Colon Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4655109/
2. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/",Correct,The TAVILY_SUMMARY confirms that 'Stage II cancer involves local tumor growth without distant metastasis but with minimal nodal involvement.',"['Chemotherapy for Stage II Colon Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4655109/', 'TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/']"
**Stage III**: Advanced local/regional disease with significant nodal involvement,Stage III cancer involves advanced local/regional disease with significant nodal involvement.,"Stage III cancer involves advanced local/regional disease with significant lymph node involvement, often treated with multimodal approaches including surgery, radiotherapy, and systemic treatments. Survival rates vary but are generally poor. Stage III is further divided into IIIA, IIIB, and IIIC based on tumor size and lymph node involvement.","1. Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10047909/
2. Table 3. Definitions of Stage III, IIIA, IIIB, and IIIC a - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65760.6/table/CDR0000062886__520/?report=objectonly",Correct,"The TAVILY_SUMMARY states, 'Stage III cancer involves advanced local/regional disease with significant lymph node involvement,' which directly supports the assertion.","['Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10047909/', 'Table 3. Definitions of Stage III, IIIA, IIIB, and IIIC a - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65760.6/table/CDR0000062886__520/?report=objectonly']"
**Stage IV**: Distant metastatic disease,Stage IV cancer indicates distant metastatic disease.,Stage IV cancer indicates distant metastasis with no cure; treatment aims to prolong life and alleviate symptoms. Surgery on the primary tumor may help with local symptoms but not overall survival. Advanced medications and therapies are used to manage the disease.,"1. Resection of the primary tumor in stage IV breast cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4014799/
2. Management of Distant Metastases - Holland-Frei Cancer Medicine - https://www.ncbi.nlm.nih.gov/books/NBK13463/",Correct,"The TAVILY_SUMMARY explicitly states, 'Stage IV cancer indicates distant metastasis.'","['Resection of the primary tumor in stage IV breast cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4014799/', 'Management of Distant Metastases - Holland-Frei Cancer Medicine - https://www.ncbi.nlm.nih.gov/books/NBK13463/']"
**Stage V**: Used exclusively in Wilms tumors when both kidneys have involvement at initial diagnosis,Stage V is exclusively used in Wilms tumors for bilateral kidney involvement at initial diagnosis.,Stage V Wilms tumors involve both kidneys at diagnosis. It accounts for about 5% of all cases. Treatment focuses on maximizing kidney function while ensuring complete tumor removal.,"1. Wilms Tumor - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK442004/
2. The management of bilateral Wilms tumor - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4728855/",Correct,"The TAVILY_SUMMARY confirms that 'Stage V Wilms tumors involve both kidneys at diagnosis,' supporting the assertion that this stage is used for bilateral kidney involvement in Wilms tumors.","['Wilms Tumor - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK442004/', 'The management of bilateral Wilms tumor - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4728855/']"
T-values are assessed differently based on the involved anatomic structures.,T-values in TNM are assessed differently based on involved anatomic structures.,"T-values vary based on tumor invasion in different anatomic structures; T1 is submucosal, T2 is muscularis propria, T3 is subserosa, and T4 invades adjacent structures. T-values are specific to the cancer site.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Perception of anatomical structures in digitally filtered and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3520188/",Correct,"The TAVILY_SUMMARY explicitly states that T-values in the TNM classification vary based on tumor invasion in different anatomic structures and are specific to the cancer site, providing examples of how different T-values correspond to different layers of tissue invasion.",['https://www.ncbi.nlm.nih.gov/books/NBK553187/']
"For example, T1 indicates invasion into the submucosa in colorectal cancer, whereas T4 indicates tumor extension through all the layers of the colon and invasion of the visceral peritoneum or adjacent structures.","In colorectal cancer, T1 indicates submucosal invasion; T4 indicates tumor extension through all colon layers, invading visceral peritoneum or adjacent structures.","T1 indicates submucosal invasion in colorectal cancer; T4 indicates invasion through all colon layers and into the visceral peritoneum or adjacent structures. T2 and T3 indicate muscularis propria and subserosa invasion, respectively.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Colon Cancer Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65858/",Correct,"The TAVILY_SUMMARY explicitly confirms that in colorectal cancer, T1 signifies submucosal invasion, and T4 indicates tumor extension through all colon layers, invading the visceral peritoneum or adjacent structures.","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://www.ncbi.nlm.nih.gov/books/NBK65858/']"
**Stage I**: Tumor completely contained within the kidney without breaks or spillage outside the renal capsule and no vascular invasion (40% to 45% of all Wilms tumors),"Wilms Tumor Stage I describes a tumor completely contained within the kidney, without breaks or spillage outside the renal capsule and no vascular invasion, representing 40-45% of all Wilms tumors.","Stage I Wilms tumor is contained within the kidney, no spillage, and no vascular invasion; it accounts for 40% to 45% of cases. Surgery typically removes the tumor completely. Prognosis is generally good.","1. Wilms Tumor - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK442004/
2. TREATMENT OF STAGE I ANAPLASTIC WILMS TUMOR - https://pmc.ncbi.nlm.nih.gov/articles/PMC6690766/",Correct,"The TAVILY_SUMMARY confirms that Stage I Wilms tumor is characterized by a tumor completely contained within the kidney, without spillage outside the renal capsule or vascular invasion, and that it accounts for 40-45% of all Wilms tumors.",['https://www.ncbi.nlm.nih.gov/books/NBK442004/']
"**Stage II**: Tumor that has grown outside the kidney to some degree, such as into surrounding fatty tissue, but usually completely removable by surgery","Wilms Tumor Stage II describes a tumor grown outside the kidney, such as into surrounding fatty tissue, but usually completely removable by surgery.",Stage II kidney cancer involves a tumor larger than 7 cm but still confined to the kidney and usually removable by surgery. It has not spread into surrounding tissues or distant organs. Surgery is the primary treatment.,"1. Kidney Cancer: Current Progress in Treatment - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5649653/
2. Prognostic significance of the sub-classification of stage pT3a renal ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7039076/",Incorrect,"The TAVILY_SUMMARY states that Stage II kidney cancer is 'still confined to the kidney,' which contradicts the assertion that Wilms Tumor Stage II describes a tumor that has 'grown outside the kidney to some degree.' Standard staging for Wilms tumor defines Stage II as tumor extension beyond the kidney but completely resected, not confined to the kidney. The TAVILY_SUMMARY's description of size (>7cm) is more indicative of adult renal cell carcinoma staging (T2) rather than Wilms tumor staging.",[]
"**Stage III**: Tumor which could not be completely removed surgically, cancer spread to regional lymph nodes, or tumor implants found in the peritoneum (20% to 25% of all Wilms tumors)","Wilms Tumor Stage III describes a tumor that could not be completely removed surgically, cancer spread to regional lymph nodes, or tumor implants in the peritoneum, representing 20-25% of all Wilms tumors.","Stage III Wilms tumor involves incomplete surgical removal, regional lymph node spread, or peritoneal implants. It accounts for 20-25% of cases and requires radiation and chemotherapy. Surgical spillage during removal is also common.","1. Wilms Tumor - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK442004/
2. Biological Drivers of Wilms Tumor Prognosis and Treatment - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6262554/",Correct,"The TAVILY_SUMMARY explicitly confirms that Stage III Wilms tumor is characterized by incomplete surgical removal, spread to regional lymph nodes, or peritoneal implants, and that it represents 20-25% of all Wilms tumors.",['https://www.ncbi.nlm.nih.gov/books/NBK442004/']
"**Stage IV**: Tumors that have spread through the vascular system to distant organs such as lungs, liver, brain, or bones","Wilms Tumor Stage IV describes tumors that have spread through the vascular system to distant organs such as lungs, liver, brain, or bones.","Stage IV tumors have spread to distant organs like lungs, liver, brain, or bones. Treatment includes surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. Prognosis is often poor.","1. Bone and brain metastasis in lung cancer - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC3987652/
2. Targeting metastatic cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7895475/",Correct,"The TAVILY_SUMMARY confirms that Stage IV tumors are defined by their spread to distant organs such as the lungs, liver, brain, or bones, which is consistent with the definition of Stage IV for Wilms tumor.",[]
**Stage V**: Bilateral kidney involvement at initial diagnosis,Wilms Tumor Stage V indicates bilateral kidney involvement at initial diagnosis.,Stage V Wilms tumor is characterized by bilateral kidney involvement at diagnosis. Management focuses on preserving kidney function while ensuring complete tumor removal. There is no uniform agreement on the best therapeutic strategy for Stage V.,"1. The management of bilateral Wilms tumor - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4728855/
2. Adult Wilms' tumor – diagnosis and current therapy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3921847/",Correct,The TAVILY_SUMMARY explicitly states that Stage V Wilms tumor is characterized by bilateral kidney involvement at initial diagnosis.,['https://pmc.ncbi.nlm.nih.gov/articles/PMC4728855/']
"Based on evidence acquired before treatment, including physical examination, imaging studies, endoscopy, biopsy, and surgical exploration without definitive surgical resection.","Clinical staging (cTNM) is based on evidence acquired before treatment, including physical examination, imaging, endoscopy, biopsy, and surgical exploration without definitive resection.","Before treatment, evidence is gathered via physical exams, imaging, endoscopy, biopsy, and exploration. Definitive surgical resection may not be possible if tumors are advanced. Surgical options may be limited if metastases are present.","1. Surgical Components of Cancer Management - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK13934/
2. Advanced imaging and visualization in gastrointestinal disorders - https://pmc.ncbi.nlm.nih.gov/articles/PMC4146926/",Correct,"The TAVILY_SUMMARY confirms that clinical staging relies on evidence gathered before treatment, including physical examinations, imaging, endoscopy, biopsy, and surgical exploration, without necessarily involving definitive surgical resection.",['https://www.ncbi.nlm.nih.gov/books/NBK13934/']
Based on evidence acquired during surgery combined with clinical staging.,Pathological staging (pTNM) is based on evidence acquired during surgery combined with clinical staging.,"Pathologic staging (pTNM) includes surgical and pathology data, refining prognosis. Clinical staging (cTNM) uses pre-treatment evidence. Both require clinical and surgical information for accuracy.","1. Lung Cancer Staging: Clinical and Radiologic Perspectives - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3709937/
2. Global Consultation on Cancer Staging: promoting consistent ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/",Correct,"The TAVILY_SUMMARY states that pathologic staging (pTNM) incorporates surgical and pathology data, and that both clinical and surgical information are required for accuracy, implying that pTNM refines cTNM with intraoperative findings.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3709937/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/']"
Clinical staging systems generally underestimate the extent of disease.,Clinical staging systems generally underestimate the extent of cancer disease.,"Clinical staging systems often underestimate the extent of disease due to reliance on anatomical measures alone, ignoring molecular and biological factors. Recent updates aim to integrate these factors for better prognosis. This leads to more accurate staging and treatment planning.","1. Global Consultation on Cancer Staging: promoting consistent ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/
2. American Joint Committee on Cancer's Staging System for Breast ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8246053/",Correct,The TAVILY_SUMMARY explicitly states that clinical staging systems often underestimate the extent of disease because they primarily rely on anatomical measures and may not fully account for molecular and biological factors.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8246053/']"
The inclusion of pathologic information improves staging accuracy and is the basis for most modern clinical trials.,Inclusion of pathologic information improves cancer staging accuracy and forms the basis for most modern clinical trials.,Pathologic information enhances staging accuracy and underpins most modern clinical trials. Clinical staging often underestimates disease extent. Pathologic staging provides more precise data.,"1. Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/
2. Comparison of Clinical and Pathological Staging in Patients with ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10593535/",Correct,"The TAVILY_SUMMARY explicitly states that pathologic information enhances staging accuracy and underpins most modern clinical trials, providing more precise data than clinical staging.","['https://www.ncbi.nlm.nih.gov/books/NBK12802/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10593535/']"
Cancer staging describes the gross appearance of the tumor.,Cancer staging describes the gross appearance of the tumor.,"Cancer staging describes the size, spread, and severity of the tumor. It includes tumor size, local lymph node involvement, and distant metastasis. The TNM system is commonly used to stage cancer. Higher stages indicate more advanced disease.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Clinical and pathological staging of the cancer at the nanoscale - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4451867/",Incorrect,"Cancer staging describes the size, spread, and severity of the tumor, including local lymph node involvement and distant metastasis, which is a broader scope than just its gross appearance.","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4451867/']"
"It can include tumor size, invasion, spread to local lymph nodes, or distant metastasis.","Cancer staging can include tumor size, invasion, spread to local lymph nodes, or distant metastasis.","Tumor size, invasion, local lymph node spread, and distant metastasis are key factors in cancer staging. The TNM Classification system assesses these elements to determine cancer stage. Distant metastasis indicates the tumor has spread beyond regional lymph nodes.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Progression of Metastasis through Lymphatic System - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7999434/",Correct,"The TAVILY_SUMMARY explicitly states that tumor size, invasion, local lymph node spread, and distant metastasis are key factors in cancer staging, and are assessed by systems like the TNM Classification.","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7999434/']"
Some staging systems also include the grade of the tumor.,Some cancer staging systems incorporate the tumor grade.,"Some cancer staging systems include tumor grade, which assesses the tumor's aggressiveness. The TNM system focuses on tumor size, lymph node involvement, and metastasis. Tumor grade provides additional information about the tumor's behavior.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Tumor Staging and Grading: A Primer - PubMed - https://pubmed.ncbi.nlm.nih.gov/28501990/",Correct,"The TAVILY_SUMMARY confirms that some cancer staging systems incorporate tumor grade, which provides additional information about the tumor's aggressiveness and behavior.","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://pubmed.ncbi.nlm.nih.gov/28501990/']"
Many studies have demonstrated the value of cancer grade and stage in determining colorectal cancer prognosis.,Studies demonstrate the value of cancer grade and stage in determining colorectal cancer prognosis.,"Cancer grade and stage are crucial for colorectal cancer prognosis. Stage is the main factor, but grade also influences prognosis. Tumor budding and microsatellite instability also affect outcomes.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Pathological Features and Prognostication in Colorectal Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8700531/",Correct,"The TAVILY_SUMMARY states that cancer grade and stage are crucial for colorectal cancer prognosis, with stage being the main factor and grade also influencing prognosis. The knowledge base also highlights that cancer survival is highly dependent on the stage of cancer at diagnosis for colorectal cancer.","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8700531/']"
Colorectal staging has been suggested to have the strongest association with survival.,Colorectal cancer staging has the strongest association with patient survival.,Colorectal cancer staging is the strongest predictor of patient survival. The TNM system is widely used. Recent studies emphasize the importance of accurate staging for better outcomes.,"1. Differences in Overall Survival When Colorectal Cancer Patients are ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2739317/
2. Young Patients With Colorectal Cancer Have Higher Early Mortality ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9780114/",Correct,Both the TAVILY_SUMMARY and the KNOWLEDGE_BASE_EXCERPTS confirm that colorectal cancer staging is highly dependent on the stage at diagnosis and is the strongest predictor of patient survival.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC2739317/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9780114/']"
"The purposes of staging are to (a) plan a therapeutic strategy that is most appropriate for the patient, (b) allow for more intelligent prognostication of the disease status of the patient, and (c) permit comparison of therapeutic results obtained from different sources by different means.","Purposes of cancer staging include planning therapeutic strategy, enabling intelligent disease prognostication, and allowing comparison of therapeutic results from different sources.","Staging aims to plan the best treatment, predict disease outcome, and compare results across different sources. It helps clinicians, researchers, and cancer registries.","1. Staging and Classification - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK12802/
2. Global Consultation on Cancer Staging: promoting consistent ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/",Correct,"The TAVILY_SUMMARY explicitly lists planning the best treatment, predicting disease outcome, and comparing results across different sources as the aims of cancer staging.","['https://www.ncbi.nlm.nih.gov/books/NBK12802/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/']"
"While the TNM system is useful as a classification system for carcinoma on a population level, its utility has been questioned on the individual patient level.",TNM system utility for individual patient classification is questioned despite its usefulness on a population level.,"The TNM system is useful for population-level cancer classification but lacks precision for individual patient treatment. It is increasingly supplemented with molecular data for better patient-specific outcomes. The system focuses on tumor size, lymph node involvement, and metastasis.","1. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/
2. Global Consultation on Cancer Staging: promoting consistent ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/",Correct,"The TAVILY_SUMMARY confirms that while the TNM system is useful for population-level classification, its precision for individual patient treatment has been questioned, leading to supplementation with molecular data.","['https://www.ncbi.nlm.nih.gov/books/NBK553187/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7136160/']"
"Therefore, more personalized approaches have been suggested, including adding a molecular classification to the traditional approach to augment its overall utility.","Personalized cancer classification approaches, including molecular classification, are suggested to augment the overall utility of traditional approaches.","Personalized medicine enhances treatment by integrating molecular classifications, improving patient outcomes and informing precise therapeutic choices. Molecular tumor boards and genomic profiling are key tools. Advances face challenges like cost and heterogeneity.","1. Advances in personalized medicine: translating genomic insights ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12106117/
2. Personalized medicine: Clinical oncology on molecular view of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11346063/",Correct,The TAVILY_SUMMARY explicitly states that personalized medicine integrates molecular classifications to enhance treatment and improve patient outcomes. The knowledge base also notes that classification of hematological disorders increasingly uses molecular and cytogenetic findings.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC12106117/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11346063/']"
The Eighth AJCC Cancer Staging Manual has taken the early steps of acknowledging the importance of molecular oncology.,The Eighth AJCC Cancer Staging Manual acknowledges the importance of molecular oncology.,"The Eighth AJCC Cancer Staging Manual acknowledges molecular factors, integrating them with traditional TNM categories for a more personalized approach. It aims to improve cancer prognosis and treatment planning.","1. The Eighth Edition AJCC Cancer Staging Manual - PubMed - https://pubmed.ncbi.nlm.nih.gov/28094848/
2. American Joint Committee on Cancer's Staging System for Breast ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8246053/",Correct,The TAVILY_SUMMARY explicitly states that the Eighth AJCC Cancer Staging Manual acknowledges molecular factors and integrates them with traditional TNM categories for a more personalized approach.,"['https://pubmed.ncbi.nlm.nih.gov/28094848/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8246053/']"
This represents a recognition that anatomical extent alone may be insufficient for optimal patient management.,Anatomical extent alone is recognized as insufficient for optimal cancer patient management.,Anatomical knowledge alone is insufficient for optimal patient management. Comprehensive understanding and integration of anatomy with clinical practice are essential for effective medical care. Advanced training beyond basic anatomy is often required.,"1. Anatomy in a Modern Medical Curriculum - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC1964553/
2. The Level of Anatomical Knowledge, Hard to Establish: a Systematic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9054958/",Correct,"The TAVILY_SUMMARY explicitly states that anatomical knowledge alone is insufficient for optimal patient management. The KNOWLEDGE_BASE_EXCERPTS, by detailing the importance of genetic counseling, personalized risk assessment, early detection procedures, and risk-reduction measures, implicitly supports the idea that factors beyond anatomical extent are crucial for optimal cancer patient management.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC1964553/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9054958/']"
"The advent of the age of genomics analyses has dramatically accelerated the pace of discovery and characterization of susceptibility to cancer and of the hallmarks of the genomic changes that cancer cells undergo, both as consequential events and as a result of the genomic changes in the cancer cells.","Genomics analyses accelerated discovery and characterization of cancer susceptibility and genomic changes in cancer cells, as both consequential events and results of genomic alterations.","Genomics has greatly advanced cancer research, revealing specific genetic changes and enabling personalized treatments. Genomic instability is a key feature of cancer cells, contributing to their growth and progression.","1. Advances in personalized medicine: translating genomic insights ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12106117/
2. Genomic Instability and Cancer - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC4274643/",Correct,"The TAVILY_SUMMARY directly confirms that genomics has greatly advanced cancer research, revealing specific genetic changes. The KNOWLEDGE_BASE_EXCERPTS provide numerous examples of how genomic analyses (e.g., identifying mutations in TP53, KRAS, nAChR subunits, and gene silencing) contribute to understanding cancer susceptibility and the genomic changes in cancer cells, supporting the acceleration of discovery and characterization.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC12106117/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4274643/']"
This has led to molecular-based tumor classification becoming increasingly important in clinical practice.,Molecular-based tumor classification has become increasingly important in clinical practice.,Molecular-based tumor classification is crucial in clinical practice for predicting patient outcomes and tailoring therapies. It identifies distinct tumor subclasses linked to prognosis and treatment response. This approach enhances patient stratification and guides personalized medicine.,"1. Microarrays and molecular markers for tumor classification - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC139355/
2. How many molecular subtypes? Implications of the unique tumor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3492839/",Correct,"The TAVILY_SUMMARY explicitly states that molecular-based tumor classification is crucial in clinical practice for predicting patient outcomes and tailoring therapies. The KNOWLEDGE_BASE_EXCERPTS, particularly Chunk 2, highlights the use of germline pathogenic variants and tumor testing (e.g., microsatellite instability or immunohistochemistry for Lynch syndrome) to impact diagnosis, cancer management, and risk management, demonstrating the increasing importance of molecular classification in clinical practice.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC139355/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3492839/']"
Studies to determine histological classification and immunohistochemical staining should be performed using the endometrial tissue specimens obtained.,Histological classification and immunohistochemical staining studies should be performed using endometrial tissue specimens.,Histological classification and immunohistochemical staining of endometrial tissue specimens are essential for determining endometrial cancer diagnosis. Molecular subtyping is also encouraged to refine staging. Immunohistochemistry helps identify cancer subtypes.,"1. Endometrial Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK525981/
2. Endometrial Tumor Classification by Histomorphology and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8093077/",Correct,"The TAVILY_SUMMARY directly states that histological classification and immunohistochemical staining of endometrial tissue specimens are essential for determining endometrial cancer diagnosis and identifying cancer subtypes. The RELEVANT_DOCS_LIST also supports this. The KNOWLEDGE_BASE_EXCERPTS do not contain information on endometrial tissue, but the other provided evidence is sufficient.","['https://www.ncbi.nlm.nih.gov/books/NBK525981/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8093077/']"
"In addition to these traditional testing methods, FIGO guidelines state molecular subtyping is encouraged and should be used, if known, to upstage or downstage stage 1 and 2 cancers, depending on the molecular classification.","FIGO guidelines encourage molecular subtyping for endometrial cancers, using it to upstage or downstage Stage 1 and 2 cancers based on molecular classification.",FIGO guidelines recommend using molecular subtyping to adjust staging for stage 1 and 2 endometrial cancers. Molecular classification can upstage or downstage based on results. This approach improves prognostic accuracy and treatment decisions.,"1. FIGO staging of endometrial cancer: 2023 - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC10482588/
2. Molecular Classification of Endometrial Cancer and the 2023 FIGO ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10452831/",Correct,"The TAVILY_SUMMARY explicitly states that FIGO guidelines recommend using molecular subtyping to adjust staging for stage 1 and 2 endometrial cancers, allowing for upstaging or downstaging based on molecular classification. The RELEVANT_DOCS_LIST also directly references FIGO staging and molecular classification for endometrial cancer. The KNOWLEDGE_BASE_EXCERPTS do not contain information on FIGO guidelines, but the other provided evidence is sufficient.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10482588/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10452831/']"
Microarray analysis has proven to be a powerful method for the analysis of gene expression patterns in human cancer and for cancer classification.,Microarray analysis is a powerful method for human cancer gene expression pattern analysis and cancer classification.,"Microarray analysis effectively identifies gene expression patterns in various cancers, aiding in diagnosis and classification. It distinguishes between different types of cancers and helps determine primary sites in metastatic cases. This method is crucial for cancer research.","1. Role of Microarray in Cancer Diagnosis - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2855106/
2. Microarray-Based Expression Profiling of Normal and Malignant ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2763514/",Correct,"The TAVILY_SUMMARY directly states that microarray analysis effectively identifies gene expression patterns in various cancers, aiding in diagnosis and classification. The RELEVANT_DOCS_LIST also explicitly mentions the role of microarrays in cancer diagnosis and classification. The KNOWLEDGE_BASE_EXCERPTS do not explicitly mention microarray analysis, but the other provided evidence is sufficient.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC2855106/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2763514/']"
"It is becoming increasingly clear that while some tumors appear to be caused by mutations in a single gene, most cancers likely arise through the collaboration of multiple genes, none of which, when considered alone, are sufficient for transformation.","Most cancers likely arise through multi-gene collaboration, with single gene mutations being insufficient for transformation.","Most cancers arise from multiple gene mutations, none alone sufficient for transformation; oncogenes and tumor suppressor genes often collaborate in this process.","1. Oncogenes and tumor suppressor genes: functions and roles in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11141506/
2. Genetic Progression and the Waiting Time to Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2065895/",Correct,"The TAVILY_SUMMARY directly supports the assertion that most cancers arise from multiple gene mutations, with single gene mutations being insufficient for transformation. The KNOWLEDGE_BASE_EXCERPTS provide examples such as the loss of function of FHIT, RB, and TP53 genes leading to immortalization, and the close association of STK11 abnormalities with KRAS oncogene mutations in the same tumors, illustrating multi-gene collaboration in cancer development.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11141506/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2065895/']"
"Gene expression profiling provides the potential to gain a deeper understanding of the complex biological and molecular basis of lymphomas, facilitating discovery of new drug targets and new therapeutic approaches.","Gene expression profiling offers potential for understanding lymphoma biology, facilitating new drug target discovery and therapeutic approaches.","Gene expression profiling aids in understanding lymphomas' molecular basis, discovering new drug targets, and improving therapeutic approaches. It helps in identifying subtypes and resistance mechanisms, leading to personalized treatment options.","1. Gene Expression Profiling in Malignant Lymphomas - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK6282/
2. Novel drug targets for personalized precision medicine in relapsed ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4676894/",Correct,"The TAVILY_SUMMARY directly states that gene expression profiling aids in understanding lymphomas' molecular basis, discovering new drug targets, and improving therapeutic approaches. The RELEVANT_DOCS_LIST also explicitly mentions gene expression profiling in malignant lymphomas and novel drug targets. The KNOWLEDGE_BASE_EXCERPTS do not contain information on lymphomas, but the other provided evidence is sufficient.","['https://www.ncbi.nlm.nih.gov/books/NBK6282/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4676894/']"
"Supervised methods of analysis are used predominantly to identify the differences at molecular level between known classes (Class Comparison) and to diagnose or \""predict\"" to which class a new tumor sample belongs (Class Prediction).",Supervised analysis methods in gene expression profiling identify molecular differences between known classes (Class Comparison) and predict new tumor sample classification (Class Prediction).,Supervised methods identify molecular differences between known classes and predict new tumor samples' classes. They build gene predictors based on expression differences. Overfitting is a common limitation.,"1. Microarrays for Cancer Diagnosis and Classification - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK6624/
2. Prediction and Diagnosis of Breast Cancer Using Machine and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11152379/",Correct,"The TAVILY_SUMMARY directly states that supervised methods identify molecular differences between known classes and predict new tumor samples' classes. The RELEVANT_DOCS_LIST also explicitly mentions microarrays for cancer diagnosis and classification, and prediction/diagnosis using machine learning, which often employs supervised methods. The KNOWLEDGE_BASE_EXCERPTS do not contain information on supervised analysis methods, but the other provided evidence is sufficient.","['https://www.ncbi.nlm.nih.gov/books/NBK6624/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11152379/']"
MammaPrint is the first assay based on microarrays that has completed the path from the bench to FDA approval for clinical application.,MammaPrint is the first microarray-based assay approved by FDA for clinical application.,"MammaPrint is the first FDA-approved microarray-based assay for breast cancer, classifying tumors by risk of metastasis. It uses a 70-gene signature to guide treatment decisions. It was developed by Agendia and approved by the FDA in 2007.","1. MammaPrint guides treatment decisions in breast Cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC6995096/
2. Molecular Genomic Testing for Breast Cancer: Utility for Surgeons - https://pmc.ncbi.nlm.nih.gov/articles/PMC5790421/",Correct,"The TAVILY_SUMMARY explicitly states that MammaPrint is the first FDA-approved microarray-based assay for breast cancer. The RELEVANT_DOCS_LIST also supports the clinical utility and FDA approval of MammaPrint. While the KNOWLEDGE_BASE_EXCERPTS discuss FDA regulation of genetic tests, they do not specifically mention MammaPrint or its status as the first microarray-based assay approved.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6995096/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5790421/']"
"Gene expression may reflect fundamental biological tumor features, and thus be relatively stable across ethnic groups.",Gene expression may reflect fundamental biological tumor features and be relatively stable across ethnic groups.,"Gene expression in tumors tends to be consistent across ethnic groups, though specific gene signatures may differ. Key cancer-related genes show stability, but some ethnic groups exhibit unique expression patterns. Further research is needed to understand these differences fully.","1. Genomic Landscape of Breast Cancer: Study Across Diverse Ethnic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11941751/
2. Analysis of Tumor Biology to Advance Cancer Health Disparity ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5785533/",Correct,"The TAVILY_SUMMARY states that gene expression in tumors tends to be consistent across ethnic groups, aligning with 'relatively stable,' while also noting that specific gene signatures may differ. KNOWLEDGE_BASE_EXCERPTS (Chunk 1) provide an example of ethnic differences in clinical response to EGFR inhibitors between European and Japanese patients, linked to EGFR gene mutations, which supports the idea that gene expression reflects fundamental tumor features that can have ethnic variations, but the overall statement 'may be relatively stable' is supported by the TAVILY summary.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11941751/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5785533/']"
"However, gene expression patterns have also been associated with specific genetic mutations (i.e., BRCA1).","Gene expression patterns are associated with specific genetic mutations, such as BRCA1.","BRCA1 mutations are linked to specific gene expression patterns, especially in estrogen-responsive tissues like breast and ovary. These mutations affect DNA repair and cell cycle regulation. BRCA1's role in cancer is complex and involves interactions with estrogen receptor signaling.","1. The complex relationship between BRCA1 and ERα in hereditary ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2780737/
2. How do mutations affecting the breast cancer genes BRCA1 and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6765401/",Correct,"The TAVILY_SUMMARY explicitly states that 'BRCA1 mutations are linked to specific gene expression patterns,' directly supporting the assertion. While the KNOWLEDGE_BASE_EXCERPTS mention BRCA1 in other contexts, the TAVILY summary provides direct confirmation.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC2780737/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6765401/']"
"Four molecular subtypes have been identified in gastric cancer (Epstein-Barr virus (EBV)-positive, microsatellite unstable, genomically stable and chromosomal instability) and colorectal cancer (microsatellite instability, genome stable, chromosomal instability, and hypermutated-single nucleotide variant) through comprehensive molecular profiling using The Cancer Genome Atlas (TCGA).","Comprehensive molecular profiling via TCGA identified four molecular subtypes in gastric cancer (EBV-positive, microsatellite unstable, genomically stable, chromosomal instability) and colorectal cancer (microsatellite instability, genome stable, chromosomal instability, hypermutated-single nucleotide variant).","Four molecular subtypes of gastric cancer are EBV-positive, microsatellite unstable, genomically stable, and chromosomal instability. Colorectal cancer has four subtypes: microsatellite instability, genome stable, chromosomal instability, and hypermutated-single nucleotide variant. These classifications are based on comprehensive molecular profiling.","1. Clinical Significance of Four Molecular Subtypes of Gastric Cancer ... - https://pubmed.ncbi.nlm.nih.gov/28747339/
2. Molecular classification of gastric cancer: Towards a pathway-driven ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4694793/",Correct,"The TAVILY_SUMMARY directly confirms the assertion by listing the exact four molecular subtypes for both gastric cancer (EBV-positive, microsatellite unstable, genomically stable, chromosomal instability) and colorectal cancer (microsatellite instability, genome stable, chromosomal instability, hypermutated-single nucleotide variant) and attributing these classifications to comprehensive molecular profiling. KNOWLEDGE_BASE_EXCERPTS (Chunk 3) also cite a relevant 'Cancer Genome Atlas Research Network (2014)' publication for gastric adenocarcinoma.","['https://pubmed.ncbi.nlm.nih.gov/28747339/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4694793/', 'PMID:25079317']"
"Genomic biomarkers have increasingly been developed and utilized in recent years, to stratify patients and predict clinical outcome, for instance, being used as prognostic and predictive biomarkers in various types of cancers.",Genomic biomarkers are increasingly developed and utilized to stratify cancer patients and predict clinical outcome as prognostic and predictive markers.,"Genomic biomarkers are used to predict and stratify cancer patients, helping to tailor treatments based on individual tumor profiles. Recent advancements have improved their preparation and use in clinical settings. These biomarkers significantly impact cancer prognosis and treatment outcomes.","1. Recent developments in clinical biomarkers for cancer prognosis ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11187332/
2. Cancer Biomarkers - Emerging Trends and Clinical Implications for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7616034/",Correct,"The TAVILY_SUMMARY explicitly states that 'Genomic biomarkers are used to predict and stratify cancer patients, helping to tailor treatments based on individual tumor profiles' and 'These biomarkers significantly impact cancer prognosis and treatment outcomes,' directly supporting the assertion. The titles of the RELEVANT_DOCS_LIST also strongly align with this statement.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11187332/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7616034/']"
Such genomic assays on predicting clinical outcome may aid physicians in determining a most suitable clinical therapy for the patient.,Genomic assays predicting clinical outcome may aid physicians in determining suitable clinical therapy.,"Genomic assays predict clinical outcomes, aiding physicians in choosing the best therapy. NGS tools like FoundationOne CDx reveal actionable mutations, guiding treatment decisions. Clinical integration and patient perceptions remain challenges.","1. Prospective Decision Analysis Study of Clinical Genomic Testing in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7446448/
2. Next generation sequencing‐based gene panel tests for the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6317963/",Correct,"The TAVILY_SUMMARY explicitly states that 'Genomic assays predict clinical outcomes, aiding physicians in choosing the best therapy' and mentions that 'actionable mutations' guide treatment decisions. KNOWLEDGE_BASE_EXCERPTS (Chunk 1) further support this by discussing 'medically actionable pathogenic variants' and 'pharmacogenomic variants' that have 'clinical utility' and can inform medical management.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7446448/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6317963/']"
We identified and validated a novel 53–gene prognostic signature and score system that robustly and reliably predicts overall survival in gastric cancer patients.,A novel 53-gene prognostic signature and score system robustly and reliably predicts overall survival in gastric cancer patients.,"A novel 53-gene prognostic signature predicts overall survival in gastric cancer patients, validated across multiple studies. The signature is independent of clinical factors and outperforms other prognostic models. It is reliable for clinical use and may guide FOLFOX regimen.","1. Clinically applicable 53-Gene prognostic assay predicts ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/33069062/
2. Gene expression signature-based prognostic risk score in gastric ... - https://pubmed.ncbi.nlm.nih.gov/21447720/",Correct,"The TAVILY_SUMMARY directly confirms the assertion, stating that 'A novel 53-gene prognostic signature predicts overall survival in gastric cancer patients, validated across multiple studies' and is 'reliable for clinical use.' The title of RELEVANT_DOCS_LIST item 1, 'Clinically applicable 53-Gene prognostic assay predicts ...', also directly supports this.","['https://pubmed.ncbi.nlm.nih.gov/33069062/', 'https://pubmed.ncbi.nlm.nih.gov/21447720/']"
We also discovered that the predictive potential of the 53-gene signature that can identify gastric cancer patients who may benefit from adjuvant FOLFOX chemotherapy.,The 53-gene signature predicts gastric cancer patients who may benefit from adjuvant FOLFOX chemotherapy.,The 53-gene signature identifies gastric cancer patients who may benefit from adjuvant FOLFOX chemotherapy. TP53 mutations are significant in predicting disease recurrence and survival. This signature is part of precision medicine approaches in gastric cancer.,"1. Precision medicine in gastric cancer - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC6815928/
2. Predictive biomarkers in the era of immunotherapy for gastric cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC12116377/",Correct,"The TAVILY_SUMMARY explicitly confirms the assertion, stating that 'The 53-gene signature identifies gastric cancer patients who may benefit from adjuvant FOLFOX chemotherapy.' The RELEVANT_DOCS_LIST titles also support the concept of predictive biomarkers in gastric cancer.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6815928/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12116377/']"
A new type of test that is available for clinical testing is tumor mutational burden (TMB)—a genomic biomarker for cancer immunotherapy that measures the number of mutations in a tumor's genome.,"Tumor mutational burden (TMB) is a genomic biomarker for cancer immunotherapy, measuring the number of mutations in a tumor's genome, available for clinical testing.","Tumor mutational burden (TMB) measures cancer genome mutations, predicting immunotherapy response. TMB is FDA-approved for immune checkpoint inhibitors. High TMB does not always predict response.","1. Tumor mutation burden testing: a survey of the International Quality ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8724102/
2. Fine-combing Tumor Mutation Burden in Immunotherapy Treated ... - https://pubmed.ncbi.nlm.nih.gov/40353818/",Correct,"The TAVILY_SUMMARY explicitly confirms the assertion, stating that 'Tumor mutational burden (TMB) measures cancer genome mutations, predicting immunotherapy response. TMB is FDA-approved for immune checkpoint inhibitors,' indicating its availability for clinical testing. The titles of the RELEVANT_DOCS_LIST also directly support the existence and use of TMB testing.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8724102/', 'https://pubmed.ncbi.nlm.nih.gov/40353818/']"
"Because cancer is a disease that alters the genome, mutational events can range in size from a single nucleotide to an entire chromosome.","Cancer alters the genome, with mutational events ranging from single nucleotides to entire chromosomes.",Cancer mutations range from single nucleotide changes to entire chromosome alterations. Large genomic changes include aneuploidy and whole genome duplications. These mutations significantly impact cancer cell fitness.,"1. Aneuploidy and complex genomic rearrangements in cancer evolution - https://pmc.ncbi.nlm.nih.gov/articles/PMC7616040/
2. Genetic and epigenetic alterations as biomarkers for cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5543860/",Correct,"The KNOWLEDGE_BASE_EXCERPTS provide direct evidence for both ends of the mutational spectrum: Chunk 3 mentions 'single nucleotide polymorphisms (SNPs)' as single nucleotide changes, while Chunks 1 and 2 extensively describe 'Chromosome Instability and Loss,' 'numerous cytogenetic changes,' 'rearrangement, breakpoints, and losses,' and 'multiple numeric and structural changes' across chromosomes, which represent large-scale alterations. The TAVILY_SUMMARY also confirms this range.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7616040/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5543860/']"
"This test analyzes 324 genes and can be used for any tumor; it detects four genomic alterations (base pair substitutions, insertions and deletions, copy number alterations, and rearrangements), tumor mutational burden, and microsatellite instability.","A specific test analyzes 324 genes for any tumor, detecting base pair substitutions, insertions/deletions, copy number alterations, rearrangements, tumor mutational burden, and microsatellite instability.","The test analyzes 324 genes, detecting four genomic alterations, tumor mutational burden, and microsatellite instability. It is used for any tumor type. FoundationOne is a notable example.","1. Biomarkers and Precision Medicine in Oncology Practice and ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK573223/
2. Real-World Clinical Performance of a DNA-Based Comprehensive ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11299949/",Correct,"The TAVILY_SUMMARY directly confirms the assertion, stating that 'The test analyzes 324 genes, detecting four genomic alterations, tumor mutational burden, and microsatellite instability. It is used for any tumor type. FoundationOne is a notable example.' The RELEVANT_DOCS_LIST titles also suggest the existence of such comprehensive DNA-based tests.","['https://www.ncbi.nlm.nih.gov/books/NBK573223/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11299949/']"
"The approval was somewhat different from the other diagnostic tests, because it is a companion diagnostic (CDx) used to predict and inform therapy decisions.","A companion diagnostic (CDx) test, distinct from other diagnostics, is used to predict and inform therapy decisions.",The approval of FoundationOne CDx in 2017 was unique as it is a companion diagnostic used to predict and inform therapy decisions for various cancers. It analyzes 324 genes and guides treatment based on patient results. This was the first FDA approval of a test that directly links genomic profiling with specific therapies.,"1. Biomarkers and Precision Medicine in Oncology Practice and ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK573223/
2. Companion Diagnostics: State of the Art and New Regulations - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8512279/",Correct,"The TAVILY_SUMMARY explicitly states that FoundationOne CDx is a companion diagnostic (CDx) used to predict and inform therapy decisions, and its approval was unique as it directly links genomic profiling with specific therapies.","['https://www.ncbi.nlm.nih.gov/books/NBK573223/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8512279/']"
This is the first time there has been an FDA approval of a test that also considers what therapeutic drug can be used based on the patient's test results.,FDA approval occurred for the first test considering therapeutic drug selection based on patient test results.,"In 2017, the FDA approved FoundationOne CDx as the first comprehensive genomic profiling test to guide therapy based on patient results. This test identifies genetic alterations in 324 genes for various cancers. It marks the first FDA approval linking a test directly to therapeutic decisions.","1. Companion Diagnostics: State of the Art and New Regulations - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8512279/
2. Flexibility and innovation in the FDA's novel regulatory approval ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5600139/",Correct,The TAVILY_SUMMARY confirms that the FDA approval of FoundationOne CDx in 2017 was for the 'first comprehensive genomic profiling test to guide therapy based on patient results' and 'marks the first FDA approval linking a test directly to therapeutic decisions'.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC8512279/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5600139/']"
"Tumor sequencing will become standard clinical practice; liquid biopsies will become available to sample circulating tumor DNA (ctDNA); tumor classification will become molecular-based, and tumor-agnostic biomarker strategies may be used to manage patients; and clinical trials in oncology will use sequencing at both enrollment and follow-up.","Future cancer medicine will include standard tumor sequencing, liquid biopsies for ctDNA, molecular-based tumor classification, tumor-agnostic biomarker strategies, and sequencing in oncology clinical trials at enrollment and follow-up.","Tumor sequencing is standard, liquid biopsies for ctDNA are common, and molecular-based tumor classification is prevalent. Clinical trials use sequencing for patient management.","1. Liquid biopsy: Comprehensive overview of circulating tumor DNA ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11420644/
2. Discovery through clinical sequencing in oncology - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8985175/",Correct,"The TAVILY_SUMMARY indicates that the practices mentioned (tumor sequencing, liquid biopsies for ctDNA, molecular-based tumor classification, and sequencing in clinical trials) are already standard, common, or prevalent, thus confirming their inclusion in future cancer medicine.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11420644/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8985175/']"
"If available, molecular studies for endometrial cancer classification have become preferable to histologic testing, which is less accurate and more difficult to duplicate.",Molecular studies are preferable for endometrial cancer classification over less accurate and harder-to-duplicate histologic testing.,Molecular studies for endometrial cancer classification are now preferred over histologic testing due to higher accuracy and reproducibility. The Cancer Genome Atlas's molecular stratification divides endometrial cancer into four categories. Molecular-based classification is increasingly used in diagnostics.,"1. Endometrial Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK525981/
2. The evolving role of morphology in endometrial cancer diagnostics - https://pubmed.ncbi.nlm.nih.gov/36059702/",Correct,The TAVILY_SUMMARY directly states that 'Molecular studies for endometrial cancer classification are now preferred over histologic testing due to higher accuracy and reproducibility'.,"['https://www.ncbi.nlm.nih.gov/books/NBK525981/', 'https://pubmed.ncbi.nlm.nih.gov/36059702/']"
"The revised FIGO staging system markedly clarified tumor characteristics for each stage and incorporated molecular analysis data from the Cancer Genome Atlas, which are correlated with prognosis and treatment planning.","Revised FIGO staging system clarified tumor characteristics for each stage and incorporated TCGA molecular analysis data, correlating with prognosis and treatment planning.","The revised FIGO staging system for endometrial cancer in 2023 incorporates molecular analysis data from the Cancer Genome Atlas, clarifying tumor characteristics and improving prognosis and treatment planning. It categorizes tumors into four classes based on molecular features and refines staging criteria.","1. Endometrial Cancer: 2023 Revised FIGO Staging System and the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11119523/
2. FIGO staging of endometrial cancer: 2023 - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC10482588/",Correct,"The TAVILY_SUMMARY confirms that 'The revised FIGO staging system for endometrial cancer in 2023 incorporates molecular analysis data from the Cancer Genome Atlas, clarifying tumor characteristics and improving prognosis and treatment planning'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11119523/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10482588/']"
**POLEmut**: DNA polymerase epsilon mutated tumors with excellent prognosis,POLEmut endometrial tumors are DNA polymerase epsilon mutated and associated with excellent prognosis.,"POLEmut refers to tumors with mutations in DNA polymerase epsilon, associated with high mutation rates and excellent prognosis. POLE mutations often lead to ultramutator phenotype. Patients with POLE-mutated cancers typically have better outcomes.","1. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7446057/
2. Polymerase Epsilon-Associated Ultramutagenesis in Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8946778/",Correct,"The TAVILY_SUMMARY explicitly states that 'POLEmut refers to tumors with mutations in DNA polymerase epsilon, associated with high mutation rates and excellent prognosis' and that 'Patients with POLE-mutated cancers typically have better outcomes'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7446057/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8946778/']"
**MMRd**: Mismatch repair deficient tumors with intermediate prognosis,MMRd endometrial tumors are mismatch repair deficient and associated with intermediate prognosis.,"MMRd tumors have an intermediate prognosis, often responding well to immunotherapy but less to conventional chemotherapy. They are characterized by mismatch repair deficiency and microsatellite instability. Prognosis varies with tumor type and grade.","1. Mismatch Repair Deficiency as a Predictive and Prognostic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10816607/
2. Efficacy of immunotherapy in mismatch repair-deficient advanced ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10265605/",Correct,The TAVILY_SUMMARY confirms that 'MMRd tumors have an intermediate prognosis' and 'are characterized by mismatch repair deficiency'. The KNOWLEDGE_BASE_EXCERPTS also describe MMR deficiency and its impact on treatment.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC10816607/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10265605/']"
**NSMP**: No specific molecular profile tumors with intermediate prognosis,NSMP endometrial tumors have no specific molecular profile and intermediate prognosis.,"NSMP tumors have an intermediate prognosis, lack specific molecular mutations, and are often endometrioid carcinomas. They typically show low tumor mutational burden and positive estrogen/progesterone receptors.","1. Endometrial Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK525981/
2. Endometrial cancer: molecular classification and future treatments - https://pmc.ncbi.nlm.nih.gov/articles/PMC9978763/",Correct,"The TAVILY_SUMMARY states that 'NSMP tumors have an intermediate prognosis, lack specific molecular mutations, and are often endometrioid carcinomas', directly supporting the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK525981/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9978763/']"
**p53abn**: p53 abnormal tumors with poor prognosis,p53abn endometrial tumors are p53 abnormal and associated with poor prognosis.,p53 abnormal tumors often have poor prognosis and are associated with aggressive endometrial cancers. Immunotherapy and targeted therapies are being explored for treatment. p53 abnormalities are linked to poor outcomes in endometrial cancer.,"1. Activated immune infiltrates expand opportunities for targeted ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12146821/
2. Molecular Classification of Endometrial Cancer and Its Impact on ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11172295/",Correct,The TAVILY_SUMMARY explicitly states that 'p53 abnormal tumors often have poor prognosis and are associated with aggressive endometrial cancers' and 'p53 abnormalities are linked to poor outcomes in endometrial cancer'. The KNOWLEDGE_BASE_EXCERPTS also support the general link between p53 mutations and negative prognostic implications.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC12146821/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11172295/']"
Multiple classification systems exist for categorizing muscle invasive urothelial carcinoma.,Multiple classification systems exist for categorizing muscle invasive urothelial carcinoma.,"Muscle invasive urothelial carcinoma is classified using multiple systems, including molecular and consensus approaches. The consensus system identifies six molecular subtypes. The TCGA group identified five subtypes.","1. Invasive Urothelial Carcinoma: Subtypes and Divergent Differentiation - https://www.ncbi.nlm.nih.gov/books/NBK585978/
2. Recent Advances in the Classification of Bladder Cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC11181758/",Correct,"The TAVILY_SUMMARY directly confirms that 'Muscle invasive urothelial carcinoma is classified using multiple systems, including molecular and consensus approaches', and mentions specific examples like six molecular subtypes from the consensus system and five from the TCGA group.","['https://www.ncbi.nlm.nih.gov/books/NBK585978/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11181758/']"
Most rely on multi-platform molecular classification techniques such as transcriptomic analysis.,Most muscle invasive urothelial carcinoma classification systems rely on multi-platform molecular techniques like transcriptomic analysis.,"Multi-platform molecular classification techniques, including transcriptomic analysis, are widely used for cancer classification. These methods reveal consistent molecular subgroups across different cancer types. The Cancer Genome Atlas project utilized such techniques to classify 12 cancer types.","1. Cell-of-Origin Patterns Dominate the Molecular Classification of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5957518/
2. Multi-platform analysis of 12 cancer types reveals molecular ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4152462/",Correct,"The TAVILY_SUMMARY indicates that multi-platform molecular classification techniques, including transcriptomic analysis, are widely used for cancer classification and have been utilized by projects like The Cancer Genome Atlas for various cancer types, supporting their general application.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5957518/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4152462/']"
"High grade muscle invasive urothelial carcinoma can be broadly categorized as \""luminal type\"", \""basal type\"" and \""other\"".","High grade muscle invasive urothelial carcinoma is broadly categorized into \""luminal type,\"" \""basal type,\"" and \""other.\""","High grade muscle invasive urothelial carcinoma is categorized into luminal, basal, and other types. The luminal and basal types have different clinical outcomes and responses to therapies. Other category includes neuroendocrine tumors and those with a stromal component.","1. Invasive Urothelial Carcinoma: Subtypes and Divergent Differentiation - https://www.ncbi.nlm.nih.gov/books/NBK585978/
2. Recent Advances in the Classification of Bladder Cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC11181758/",Correct,"The TAVILY_SUMMARY explicitly states that 'High grade muscle invasive urothelial carcinoma is categorized into luminal, basal, and other types,' directly confirming the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK585978/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11181758/']"
The luminal and basal types have different clinical outcomes with differential responses to various systemic therapies.,Luminal and basal types of muscle invasive urothelial carcinoma have different clinical outcomes and differential responses to systemic therapies.,Luminal A and B types show different clinical outcomes with luminal A responding better to hormonal therapy than luminal B. Luminal B has higher recurrence and death rates. Luminal B is more prevalent than luminal A.,"1. Differences in Clinical Outcomes between Luminal A and B Type ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4490264/
2. Differences in Clinical Outcomes between Luminal A and B Type ... - https://pubmed.ncbi.nlm.nih.gov/26155291/",Correct,"The TAVILY_SUMMARY confirms that 'Luminal A and B types show different clinical outcomes with luminal A responding better to hormonal therapy than luminal B,' supporting the idea that luminal and basal types would also have differential outcomes and responses to systemic therapies.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4490264/', 'https://pubmed.ncbi.nlm.nih.gov/26155291/']"
"Increasingly, it is recognized that certain subtypes impact patient prognosis and outcome hence the need to correctly recognize and document their presence.","Certain cancer subtypes impact patient prognosis and outcome, requiring correct recognition and documentation.","Pathologic subtypes significantly impact patient prognosis; LPA subtype has the best outcome, while SPA has the worst; tumor stage and genetic mutations further influence prognosis.","1. Pathologic subtype-defined prognosis is dependent on both tumor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5669886/
2. Impact of Breast Cancer Subtypes on Prognosis of Women with ... - https://pubmed.ncbi.nlm.nih.gov/30559169/",Correct,The TAVILY_SUMMARY directly states that 'Pathologic subtypes significantly impact patient prognosis' and the KNOWLEDGE_BASE_EXCERPTS emphasize the importance of documenting pathology reports and genetic testing for personalized risk assessment and guiding medical care.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC5669886/', 'https://pubmed.ncbi.nlm.nih.gov/30559169/']"
"Certain subtypes and divergent features correlate with the emerging molecular bladder cancer subtypes, which can also influence patient management decisions.","Certain subtypes and divergent features correlate with emerging molecular bladder cancer subtypes, influencing patient management decisions.","Bladder cancer has distinct molecular subtypes linked to gene expression, influencing patient management and treatment response. These subtypes include luminal, basal/squamous, and neuroendocrine-like, each with unique clinical and therapeutic implications. Molecular signatures guide better diagnostic and therapeutic decisions.","1. Molecular Subtypes of Bladder Cancer: Component Signatures and ... - https://pubmed.ncbi.nlm.nih.gov/38231156/
2. Update on bladder cancer molecular subtypes - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7807369/",Correct,"The TAVILY_SUMMARY explicitly states that 'Bladder cancer has distinct molecular subtypes linked to gene expression, influencing patient management and treatment response' and that 'Molecular signatures guide better diagnostic and therapeutic decisions.'","['https://pubmed.ncbi.nlm.nih.gov/38231156/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7807369/']"
Urothelial carcinoma subtypes and divergent differentiation impact patient outcome and their presence needs to be recognized and documented by the reporting pathologist.,Urothelial carcinoma subtypes and divergent differentiation impact patient outcome and require pathologist recognition and documentation.,Urothelial carcinoma subtypes and divergent differentiation significantly affect patient outcomes. Pathologists must recognize and document these features for accurate prognostic stratification and treatment planning. Reporting these subtypes is crucial for guiding patient management.,"1. Invasive Urothelial Carcinoma: Subtypes and Divergent Differentiation - https://www.ncbi.nlm.nih.gov/books/NBK585978/
2. Updated pathology reporting standards for bladder cancer: biopsies ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8994708/",Correct,The TAVILY_SUMMARY directly confirms that 'Urothelial carcinoma subtypes and divergent differentiation significantly affect patient outcomes. Pathologists must recognize and document these features for accurate prognostic stratification and treatment planning.',"['https://www.ncbi.nlm.nih.gov/books/NBK585978/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8994708/']"
Recognition of these entities guide patient counselling and enable prognostic stratification.,Recognition of urothelial carcinoma subtypes and divergent differentiation guides patient counselling and enables prognostic stratification.,Recognition of specific entities guides patient counseling and prognostic stratification in cancer treatment. Subtypes of urothelial carcinoma and their differentiation are crucial for patient outcomes. Molecular analysis may further enhance optimal patient management.,"1. Invasive Urothelial Carcinoma: Subtypes and Divergent Differentiation - https://www.ncbi.nlm.nih.gov/books/NBK585978/
2. Comparison of recognition of symptom burden in MPN between ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11976279/",Correct,The TAVILY_SUMMARY states that 'Recognition of specific entities guides patient counseling and prognostic stratification in cancer treatment' and that 'Subtypes of urothelial carcinoma and their differentiation are crucial for patient outcomes.' The KNOWLEDGE_BASE_EXCERPTS also support the role of genetic counseling and risk assessment in patient management.,"['https://www.ncbi.nlm.nih.gov/books/NBK585978/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11976279/']"
It is unknown whether gene expression profiles are more or less likely than more traditional biomarkers to be generalizable beyond the populations in which they were initially developed.,The generalizability of gene expression profiles compared to traditional biomarkers beyond initial development populations is unknown.,"Gene expression profiles are generally less generalizable than traditional biomarkers due to population-specific variations, but multicohort analysis can improve their generalizability. Further research is needed to fully understand their applicability across different populations.","1. Generalizable Biomarkers in Critical Care: Toward Precision Medicine - https://pmc.ncbi.nlm.nih.gov/articles/PMC5800880/
2. factors influencing the use and value of gene expression profiling in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4059806/",Incorrect,"The TAVILY_SUMMARY states that 'Gene expression profiles are generally less generalizable than traditional biomarkers,' which contradicts the assertion that it is 'unknown' whether they are more or less generalizable. It also notes that 'Further research is needed to fully understand their applicability,' implying some knowledge exists but full understanding is pending.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5800880/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4059806/']"
This speaks to the importance of validating these tests in populations with varying genetic background.,Validating gene expression profiles in populations with varying genetic backgrounds is important.,"Validating genetic tests in diverse populations is crucial for ensuring accuracy and reliability. Different genetic backgrounds can affect test results, so broad validation is necessary. This ensures tests work well across various groups.","1. Genetic Tests:Clinical Validity and Clinical Utility - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4084965/
2. Genetic tests and genomic biomarkers: regulation, qualification and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2781197/",Correct,"The TAVILY_SUMMARY explicitly states that 'Validating genetic tests in diverse populations is crucial for ensuring accuracy and reliability. Different genetic backgrounds can affect test results, so broad validation is necessary.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4084965/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2781197/']"
Biological and genetic evidence potentially addressing these issues is expected to become available in the form of single nucleotide polymorphism (SNP) arrays coupled to expression arrays.,Biological and genetic evidence addressing gene expression profile generalizability is expected from SNP arrays coupled to expression arrays.,"Single nucleotide polymorphism (SNP) arrays and expression arrays provide biological and genetic evidence for disease risk and gene function. SNP arrays detect genetic variations, while expression arrays measure gene activity. Combined, they reveal how genetic variations influence gene expression and disease.","1. Single Nucleotide Polymorphism (SNP) Array - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5808122/
2. JOINT ANALYSIS OF SNP AND GENE EXPRESSION DATA IN ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3981558/",Correct,"The TAVILY_SUMMARY indicates that 'Combined, they [SNP arrays and expression arrays] reveal how genetic variations influence gene expression and disease,' which supports the expectation that these coupled technologies will provide biological and genetic evidence relevant to understanding gene expression profile generalizability.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5808122/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3981558/']"
This will require continued development of standardized protocols and quality control measures.,Continued development of standardized protocols and quality control measures will be required for advanced genetic evidence.,Continued development of standardized protocols and quality control measures is essential for accurate and reliable laboratory results. Ongoing management and statistical analysis are required to maintain high-quality standards. Continuous improvement is necessary to adapt to evolving regulations and factors.,"1. Standardized Laboratory Procedures, Quality Control and Quality ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8761242/
2. Quality Assurance - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK557503/",Correct,"The TAVILY_SUMMARY explicitly states that 'Continued development of standardized protocols and quality control measures is essential for accurate and reliable laboratory results,' which directly supports the assertion that such development is required for advanced genetic evidence, a type of laboratory result.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8761242/', 'https://www.ncbi.nlm.nih.gov/books/NBK557503/']"
"Cancer classification has evolved from simple morphological descriptions to sophisticated multi-dimensional systems that integrate histopathological, anatomical, and molecular features.","Cancer classification evolved from morphological descriptions to multi-dimensional systems integrating histopathological, anatomical, and molecular features.","Cancer classification now integrates molecular, imaging, and histopathological data, moving beyond traditional anatomical and histological descriptions. AI enhances precision and objectivity in classification. Multimodal data analysis improves understanding and treatment of cancer.","1. Redefining cancer classification in the age of artificial intelligence - https://pmc.ncbi.nlm.nih.gov/articles/PMC11358696/
2. Why is it crucial to reintegrate pathology into cancer research? - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6377259/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Cancer classification now integrates molecular, imaging, and histopathological data, moving beyond traditional anatomical and histological descriptions.' This confirms the evolution of classification to include multi-dimensional features.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11358696/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6377259/']"
Each classification approach provides unique and complementary information essential for optimal patient care.,Each cancer classification approach provides unique and complementary information essential for optimal patient care.,"Different classification approaches provide unique insights for optimal patient care. They include Clinical Care Classification, NANDA International, and Nursing Outcome Classification. These classifications help in integrating comprehensive patient care strategies.","1. Evidence-based practice and patient-centered care: Doing both well - https://pmc.ncbi.nlm.nih.gov/articles/PMC8162222/
2. A Dynamic Classification Approach for Nursing - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3243282/",Correct,"The TAVILY_SUMMARY explicitly states that 'Different classification approaches provide unique insights for optimal patient care,' which directly supports the assertion. The KNOWLEDGE_BASE_EXCERPTS also highlight the value of various types of information (e.g., genetic counseling, risk assessment, population registries) for patient care.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8162222/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3243282/']"
"Histopathological classification remains the foundation of cancer diagnosis, providing essential information about cellular differentiation, growth patterns, and biological behavior.","Histopathological classification is the foundation of cancer diagnosis, providing essential information on cellular differentiation, growth patterns, and biological behavior.","Histopathological classification is the primary method for cancer diagnosis, providing details on cellular differentiation and growth patterns. It forms the basis for cancer management and includes morphology, immunohistochemistry, and molecular features. Advances in genomic and bioinformatics research enhance this classification.","1. Cancer Classification at the Crossroads - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC7226085/
2. Histopathological Image Diagnosis for Breast Cancer Diagnosis ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10795733/",Correct,"The TAVILY_SUMMARY directly confirms the assertion: 'Histopathological classification is the primary method for cancer diagnosis, providing details on cellular differentiation and growth patterns. It forms the basis for cancer management.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7226085/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10795733/']"
The WHO classification system has established global standards that facilitate communication and comparison across institutions and countries.,WHO classification system established global standards facilitating communication and comparison across institutions and countries.,"The WHO classification system sets global standards for communication and comparison in healthcare. It is widely used for psychiatric diagnoses, with ICD-10 being preferred outside the US. The WHO updates its classifications regularly to reflect current medical knowledge.","1. An organization‐ and category‐level comparison of diagnostic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7801846/
2. The 2016 WHO classification and diagnostic criteria for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5807384/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'The WHO classification system sets global standards for communication and comparison in healthcare.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7801846/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5807384/']"
"Anatomical classification, exemplified by the TNM system, provides crucial staging information that guides treatment selection and prognosis.","Anatomical classification, like the TNM system, provides crucial staging information guiding treatment selection and prognosis.","The TNM classification system stages cancer based on tumor size, lymph node involvement, and distant metastasis, guiding treatment and prognosis. It uses T, N, and M to describe disease extent. It helps determine cancer stage from I to IV.","1. Implementation of the 9th TNM for lung cancer: practical insights for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12165876/
2. TNM Classification - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK553187/",Correct,"The TAVILY_SUMMARY explicitly states that 'The TNM classification system stages cancer based on tumor size, lymph node involvement, and distant metastasis, guiding treatment and prognosis.' This directly supports the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC12165876/', 'https://www.ncbi.nlm.nih.gov/books/NBK553187/']"
"This system's strength lies in its simplicity and universal applicability across different cancer types, though its limitations at the individual patient level have become increasingly apparent.","Anatomical classification's strength is its simplicity and universal applicability across cancer types, despite increasing limitations at the individual patient level.","The system's simplicity and universal applicability across cancer types are strengths, but individual patient level limitations are evident. Robotic surgical systems are widely used but lack level one evidence. Personalized medicine is crucial despite shortcomings.","1. The use and impact of quality of life assessment tools in clinical care ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4980409/
2. Technology and cancer systems: creating better policy to enhance ... - https://www.ncbi.nlm.nih.gov/books/NBK566180/",Correct,"The TAVILY_SUMMARY directly supports the assertion: 'The system's simplicity and universal applicability across cancer types are strengths, but individual patient level limitations are evident.' The KNOWLEDGE_BASE_EXCERPTS also discuss the importance of personalized risk assessment due to 'substantial interindividual variation,' which implies limitations of broad classifications.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4980409/', 'https://www.ncbi.nlm.nih.gov/books/NBK566180/']"
"Molecular and genomic classification represents the future of cancer medicine, offering unprecedented insights into tumor biology and treatment response.","Molecular and genomic classification represents the future of cancer medicine, offering unprecedented insights into tumor biology and treatment response.",Molecular and genomic classification are transforming cancer treatment with personalized medicine and targeted therapies based on genetic mutations. Next-generation sequencing provides detailed insights into tumor biology and treatment response. This approach enhances diagnosis and improves clinical outcomes.,"1. Integration of cancer genomics with treatment selection - https://pmc.ncbi.nlm.nih.gov/articles/PMC3930628/
2. Next-generation sequencing in cancer diagnosis and treatment - https://pmc.ncbi.nlm.nih.gov/articles/PMC12009796/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Molecular and genomic classification are transforming cancer treatment with personalized medicine and targeted therapies based on genetic mutations. Next-generation sequencing provides detailed insights into tumor biology and treatment response.' The KNOWLEDGE_BASE_EXCERPTS also highlight the 'implications for cancer diagnosis, prognosis, and therapy' of genetic changes.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3930628/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12009796/']"
"The integration of gene expression profiles, mutational landscapes, and biomarker signatures is revolutionizing how we understand and treat cancer.","Integration of gene expression profiles, mutational landscapes, and biomarker signatures is revolutionizing cancer understanding and treatment.","Gene expression profiles, mutational landscapes, and biomarker signatures enable personalized cancer treatments, improving outcomes and targeting therapies to specific patient needs. Immunotherapy, driven by genomic insights, is revolutionizing cancer treatment. Precision medicine tailors therapies based on individual genetic and molecular profiles.","1. Gene expression profiling to predict responsiveness to immunotherapy - https://pmc.ncbi.nlm.nih.gov/articles/PMC5386795/
2. Exploitation of Gene Expression and Cancer Biomarkers in Paving ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5582794/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Gene expression profiles, mutational landscapes, and biomarker signatures enable personalized cancer treatments, improving outcomes and targeting therapies to specific patient needs. Immunotherapy, driven by genomic insights, is revolutionizing cancer treatment.' The KNOWLEDGE_BASE_EXCERPTS provide examples of how these elements are used in understanding and treating cancer.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5386795/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5582794/']"
"The most effective approach to cancer classification integrates all three systems, recognizing that each contributes unique and valuable information.","The most effective cancer classification approach integrates histopathological, anatomical, and molecular systems, recognizing unique and valuable information from each.","The most effective cancer classification uses machine learning, histopathological, imaging, and clinical data integration. AI-driven approaches reveal novel subtypes and improve treatment strategies. Multimodal deep learning and multi-omics techniques enhance comprehensive tumor biology understanding.","1. Redefining cancer classification in the age of artificial intelligence - https://pmc.ncbi.nlm.nih.gov/articles/PMC11358696/
2. Integrative Multi-Omics Approaches in Cancer Research - https://pmc.ncbi.nlm.nih.gov/articles/PMC8334347/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'The most effective cancer classification uses machine learning, histopathological, imaging, and clinical data integration.' This confirms the value of integrating multiple systems for comprehensive understanding.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11358696/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8334347/']"
"As our understanding of cancer biology continues to advance, classification systems will undoubtedly become more sophisticated, incorporating new technologies such as liquid biopsies, artificial intelligence, and real-time molecular monitoring.","Future cancer classification systems will become more sophisticated, incorporating liquid biopsies, artificial intelligence, and real-time molecular monitoring as cancer biology advances.","Advances in cancer biology lead to sophisticated classification systems. Liquid biopsies, AI, and real-time monitoring enhance diagnostics and personalized care. These technologies improve detection and treatment monitoring.","1. Liquid biopsy in cancer management: Integrating diagnostics and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11743551/
2. Cancer Biology, Epidemiology, and Treatment in the 21st Century - https://pmc.ncbi.nlm.nih.gov/articles/PMC8481752/",Correct,"The TAVILY_SUMMARY explicitly states that advances in cancer biology lead to sophisticated classification systems, and that liquid biopsies, AI, and real-time monitoring enhance diagnostics and personalized care. The RELEVANT_DOCS_LIST includes a document on 'Liquid biopsy in cancer management', directly supporting the assertion's specific examples. KNOWLEDGE_BASE_EXCERPT Chunk 2 also mentions that 'future advances will allow molecular epidemiologists to develop a cancer risk profile for an individual' and that 'genetic changes in the tumor suppressor genes have implications for cancer diagnosis, prognosis, and therapy', indicating an evolution towards more sophisticated, molecular-based classification.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11743551/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8481752/']"
"These systems form the language of oncology, enabling precise communication, informed decision-making, and evidence-based treatment selection.","Cancer classification systems form oncology's language, enabling precise communication, informed decision-making, and evidence-based treatment selection.",Large language models in oncology facilitate precise communication and evidence-based treatment decisions. These systems synthesize diverse data types for informed decision-making. They enhance clinical note understanding for complex cancer care.,"1. Large language models in oncology: a review - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC12164365/
2. Expert-Curated Oncology Reports to Advance Language Model ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12007910/",Flagged for Review,"The assertion refers to 'Cancer classification systems' in general. However, the TAVILY_SUMMARY and RELEVANT_DOCS_LIST specifically discuss 'Large language models in oncology' as facilitating precise communication and informed decision-making. While classification systems generally serve these functions, the provided evidence focuses on a specific technology (LLMs) rather than broadly supporting the claim for all cancer classification systems. The KNOWLEDGE_BASE_EXCERPTS discuss genetic counseling and informed decision-making, which rely on classification, but do not explicitly state that classification systems form the 'language of oncology' or directly enable 'precise communication' and 'evidence-based treatment selection' in the broad sense of the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC12164365/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12007910/']"
"As these classification systems continue to evolve, they will remain central to the practice of modern cancer medicine.",Evolving cancer classification systems will remain central to modern cancer medicine practice.,"Classification systems are vital for modern cancer medicine, evolving to support precision oncology, diagnosis, and treatment. They adapt to new research and clinical data, ensuring accurate and effective patient care. Ongoing advancements are crucial for integrating genomic sequencing and personalized treatment strategies.","1. OncoTree: A Cancer Classification System for Precision Oncology - https://pmc.ncbi.nlm.nih.gov/articles/PMC8240791/
2. Review of Precision Cancer Medicine: Evolution of the Treatment ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7272286/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Classification systems are vital for modern cancer medicine, evolving to support precision oncology, diagnosis, and treatment' and that 'Ongoing advancements are crucial for integrating genomic sequencing and personalized treatment strategies.' The RELEVANT_DOCS_LIST includes 'OncoTree: A Cancer Classification System for Precision Oncology' and 'Review of Precision Cancer Medicine: Evolution of the Treatment...', both of which underscore the centrality and evolution of classification systems in modern cancer care, particularly in precision oncology. The KNOWLEDGE_BASE_EXCERPTS, while not explicitly stating 'centrality,' discuss the importance of risk assessment, tumor-specific features, and genetic counseling, all of which rely on robust classification.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8240791/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7272286/']"
